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ABSTRACT
Paclitaxel is a natural plant product derived from bark of the Pacific Yew Tree. The
secondary metabolite has been extensively studied and developed as an anticancer agent
for the treatment of ovarian, breast, and lung cancer. A significant issue with the drug is
its low water solubility⏤ requiring the utilization of drug vehicles for effective drug
administration. Two novel paclitaxel-containing drugs, Cu5Fe5PAC and
(CUPAC)5GLU12DALB, are synthesized and tested against the National Cancer
Institute’s sixty cell line panel for anticancer activity. The drugs are also analyzed using
MALDI-TOF-MS, FT-IR, and 1H-NMR. One major concern with paclitaxel is the
toxicity associated with conventional intravenous therapy. Trials are conducted to
evaluate the efficacy of inhaled vaporized paclitaxel for the treatment of lung cancer. The
trials utilize two vapor devices: the KangerTech Top EVOD Vapor Pen and the Volcano
Medic II by Storz and Bickel. The purpose of the vaporization trials is to evaluate the
capability of paclitaxel to be vaporized into a nanodroplet. The vaporization tests are
conducted with a variable temperature setting and at set temperatures with various
combinations of propylene glycol/vegetable glycerin. Results are evaluated through the
assessment of vapor weight and LC-MS. Vaporization and inhalation allow for the direct
application of the pharmaceutical agent. This will lower the dose needed, and as an
effect, reduce the side effects.
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INTRODUCTION

Paclitaxel is a secondary metabolite produced from the Pacific Yew Tree that has
demonstrated antitumor properties. Development of the drug has spanned over 50 years
and its success results from the contributions of many researchers. The drug progressed
through clinical trials while researchers worked to find a solution for the agent’s supply
issue. Paclitaxel was approved for use in December 19921 and soon became one of the
most successful cancer drugs in history.2 The drug’s antitumor activity has been the basis
of creating new paclitaxel-containing drugs that utilize other delivery methods to enhance
its effects, decrease toxicity, and promote better patient outcomes.3
1.1 Discovery of Paclitaxel
1.1.1 Isolation
The National Cancer Institute (NCI) was established in 1937 with the goals of advancing
and supporting cancer research. In 1955, the Cancer Chemotherapy National Service
Center (CCNSC) was created by the NCI for the discovery and development of new
chemotherapeutic drugs. This program was created to explore and clinically evaluate new
compounds with potential anti-cancer properties. When initially founded, the focus of the
CCNSC was on testing of synthetic compounds, with only 1,500 natural products having
been tested. In 1960, a partnership was created with the United States Department of
Agriculture (USDA) to evaluate plants for potential antitumor activity.4
The USDA’s Eastern Regional Research Laboratory received samples which included
bark, twigs, fruits and leaves of the Pacific Yew tree, Taxis brevifolia. These samples

2
were sent to the Research Triangle Institute (RTI) in 1964 due to the group’s interest in
plants with 9KB activity.1 Bioactivity-guided isolation of paclitaxel occurred in June
1966 via alcohol extraction. The initial isolation process began with 12 kg of bark and
stem and resulted in 0.5 g of paclitaxel, indicating a yield of 0.004%. In vivo bioassay
monitoring was utilized throughout the process by observation of Walker 256 WM solid
tumor inhibition.1 A T/C value (treated to control value) was utilized to determine
activity. The T/C value is given as a percentage, where T represents tumor weight of
treated animal and C represents tumor weight of control animal. The following
parameters are utilized by the NCI to determine drug activity level: high activity (T/C
≤15%), intermediate activity (15%< T/C ≤45%), and low activity (T/C >45%).5 Countercurrent treatments were utilized during purification to avoid changes to the chemical
composition of the product.1
1.1.2 Determination of Structure
The structure of paclitaxel was determined using many spectrometry methods which
include infrared, mass and ultraviolet. Mass spectrometry revealed a formula of
C47H51NO14 with a molecular weight of 853 g/mol. Researchers at RTI hypothesized that
the structure contained a taxane skeleton based on familiarity with other taxane
derivatives. It was later identified that the structure contained esters attached to a taxane
nucleus.1 Base catalyzed methanolysis was used to determine the chemical’s constituents
which included: an α-hydroxy methyl ester containing nitrogen, a tetraol, and methyl
acetate.6
The full compound was unable to be analyzed using X-ray analysis, however, the αhydroxy ester and tetraol were both suitable for testing. X-ray analysis determined the
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structures of these two constituents. Final structure determination concluded two esters
were attached to the tetraol at C10 and C13. The C13 holds the α-hydroxy ester containing
two phenyl groups, one having an amide attached. This portion is of particular interest
because its presence is necessary for paclitaxel to have antitumor activity. Testing
revealed that the methyl ester component had no activity. Activity of the tetraol only
demonstrated a small fraction (1/1000) of the activity of the full compound. The αhydroxy ester, therefore, likely contributes to the activity of the compound despite its
ability to be easily cleaved from the molecule. The four-membered oxide ring is also
unique, as other taxanes lack this moiety. The structural results were published in 1971,
seven years following the initial investigation into Taxis brevifolia (see Figure 1.1 for
structure). Paclitaxel then became known as the first taxane complex exhibiting tumor
inhibitory properties.6

Figure 1.1.

Structure of paclitaxel.7
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1.2 Clinical Development
1.2.1 Activity in Tumor Systems
The Cancer Chemotherapy National Service Center (CCNSC) drug development
program, when established in 1955, selected several murine tumor models to be utilized
for testing of all drugs that were explored through the program. Initially, these in vivo
screenings consisted of L1210 leukemia, sarcoma 180, and mammary adenocarcinoma
755. The initial screening selections have changed over the years to obtain the best
understanding of potential drug activity with initial testing.8 In 1965, the NCI changed
the tumor screenings to include L1210 leukemia and Walker carcinoma 256 (WM-256).9
Paclitaxel was screened in 1967 for both tumors10; tumor inhibition activity was moderate
in L1210 leukemia1 and highly active in WM-256.6
Screenings for new drugs entering the CCNSC program were changed again in 1968 to
L1210 leukemia and P388 leukemia.9 Paclitaxel, therefore, was tested against P388
leukemia and tumor inhibition activity was highly active. Additionally, it was tested
against P1534 leukemia and demonstrated high inhibitory activity.6 These results were
promising but did not give paclitaxel an advantage over other drugs being studied.4 In
1971-72, the NCI added B16 melanoma and Lewis lung carcinoma to their initial
screening regimen.9 Paclitaxel was tested against B16 melanoma in 197410 and showed
notably high inhibitory activity, ultimately leading the drug to be considered for clinical
development.1
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1.2.2 Mechanism of Action
Many researchers were interested in discovering if paclitaxel had a unique mechanism of
action since its structure was unlike any other known taxane molecule. An initial study
into the mechanism showed that paclitaxel ceased the cell cycle at the G2-M phase
(specifically at the spindle assembly checkpoint) and disrupted mitosis. This put
paclitaxel in a group of natural products known as spindle poisons.11,1 During prophase, a
spindle structure is formed by microtubules to attach and pull chromosomes. In anaphase,
these structures begin to depolymerize to progress the cell cycle. Drugs that were
previously classified as spindle poisons have all been shown to inhibit microtubule
assembly; however, paclitaxel acts in the opposite way by stabilizing microtubule
assembly.12
The group, led by Dr. Susan Horwitz of Albert Einstein Medical Center, were the first to
determine this unique mechanism of action in 1979. Their studies determined that
addition of paclitaxel in vitro reduced the amount of tubulin, a critical component to
microtubule assembly, that was needed. The microtubules that were polymerized with the
drug present were also shorter than normal, with the average length being 1.49 ± 0.65 μm
as compared to control values (4.12 ± 2.12 μm). These shorter microtubules allowed for
an increase in presence of microtubules by 3.8-fold, which creates a more stable
structure. It was suggested that altered microtubules include a binding site for paclitaxel
that stabilizes its structure and inhibits depolymerization, even in response to factors that
would cause their normal break down.12
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1.2.3 Clinical Trials
Phase I clinical trials for paclitaxel began in 1984 and tested the molecule against many
cancer types.10 There were doubts if the trial would be successful due to patients having
issues with toxicity and allergic reactions to the drug, including anaphylaxis. These
adverse events were contributed to paclitaxel’s poor water solubility and the need for
high doses to meet optimal levels.4
A new formulation for paclitaxel was necessary for it to be suitable for clinical use. A
solubilizing agent was developed that utilized polyoxyethylated castor oil (Cremophor
EL). This component was added to paclitaxel for delivery via intravenous infusion. The
combination was given the trade name Taxol. Polyoxyethylated castol oil has been
associated with hypersensitivity reactions and can cause these issues in patients receiving
paclitaxel. Pre-treatment with antiallergy medications is recommended to avoid these
symptoms.7
Phase II clinical trials began after the slow progress through phase I trials. Taxol was
studied in ovarian cancer and showed a 30% objective response rate (ORR) in patients.13
The ORR value indicates a measurable decrease in tumor size. The response of ovarian
cancer to paclitaxel brought additional interest to the drug. Separate studies confirmed
activity against other cancer types including metastatic breast cancer with an ORR of
56%14, non-small cell lung cancer with an ORR of 24%15, malignant melanoma with an
ORR of 14%16, lymphoma with an ORR of 17%17 and head and neck cancer with an
ORR of 40%.18
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1.3 Chemical Development
A critical issue in the development of paclitaxel was the quantity of the taxane available.
After determination of the structure, the group at RTI requested more plant materials be
gathered so further testing could be undertaken. This proved to be a difficult task, as tree
supply was very limited.1 The concentration of paclitaxel in bark is also in low quantities,
ranging from 0.001-0.05% in Taxus brevifolia.19 Bark supplies were collected in Oregon
from 1976 to 1989, allowing for an adequate supply for preclinical and clinical testing.
Additionally, 1.6 million pounds of bark was obtained from trees located on government
property in 1991 and 1992, resulting in production of hundreds of kilograms of
paclitaxel. Although helpful, this did not address the long-term supply needs. This led to
researchers exploring other Yew tree species for material extraction, as well as working
on drug synthesis. The NCI began holding workshops in 1990 and 1992 to promote and
accelerate paclitaxel research.4 The supply issue was alleviated by the time a new drug
application (NDA) was submitted in 1992.1
1.3.1 Semisynthesis
The first semisynthesis of paclitaxel was accomplished by a group led by Pierre Potier at
the Institute of Chemistry of Natural Substances (part of the Scientific Research National
Center) in France. The group completed a partial synthesis utilizing a minor chemical
constituent of paclitaxel, 10-Deacetyl baccatin III, obtained from leaves of another Yew
species, Taxus baccata. It was noted that leaves from this tree regenerate quickly, so
harvesting will not negatively affect the tree population. The group was able to yield 1
g/kg of leaves. 10-Deacetyl baccatin III itself was studied and was shown to be much less
active than paclitaxel. The semisynthetic process resulted in an 89% yield of paclitaxel,
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with structural components being identical to naturally derived paclitaxel.20 This method
also led to the discovery of a paclitaxel analog, Taxotere, that also demonstrated
antitumor activity.21
Another group, led by Robert Holton at Florida State University, was also working on a
semisynthetic method for paclitaxel production. The team concluded their initial findings
in their patent filed in May of 1991. The patent described their process of using
Oxazinone, a heterocyclic compound, reacted with alcohol to form β-amido ester, which
is an intermediate for paclitaxel synthesis.22 The next year in December of 1992, the
group had established another semisynthesis of the compound utilizing β-lactam and an
alcohol to form a paclitaxel intermediate, which is then used for its synthesis.23 Both
processes utilized methods established from the Potier group.19 Under a ground-breaking
CRADA (cooperative research and development agreement), the FSU group licensed
their patent to Bristol-Myers Squibb. The company is currently using the same
semisynthetic technique for large-scale production of paclitaxel today.24,7
1.3.2 Total Synthesis
Following the semisynthetic processes, many groups began working on paclitaxel’s total
synthesis. By 1992, there were around 30 different groups working to discover a
successful method of production.25 Two groups proved to be successful and completed
their findings at nearly the same time. The first group was led by Robert Holton, who had
already succeeded in a semisynthetic process. The process discovered by Holton’s group
for paclitaxel total synthesis was published in December 1993.26 Two months later, a
total synthesis publication was released by another group headed by Kyriacos Nicolaou
of the Scripps Research Institute.27 Neither production method proved to be practical due
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to the lengthy process, complex structure of paclitaxel, and low yields.28 However, the
groups hoped their findings could help contribute to further developments and provide
useful information about the natural product.1
1.3.3 Other Production Methods
Many researchers have searched for the best solution for large-scale production of
paclitaxel. Numerous methods for production have been proposed since many were not
deemed as commercially viable options. By studying the inner phloem- cambium tissue
of Taxus brevifolia, one group discovered that an endophytic fungus had the ability to
produce paclitaxel. This discovery was made through analysis of 200 different
microorganisms from 25 T. brevifolia trees. The only organism demonstrating paclitaxel
production activity was Taxomyces andreanae. However, this method was also not
practical due to yields only being around 15-20%.29 Inducing taxane biosynthesis has also
been explored. A group found that paclitaxel and Baccatin III production could be
increased by addition of methyl jasmonate to culture medium. They added the signal
transducer to suspension cultures of various Taxus species. T. media showed the highest
production of paclitaxel at 0.606% with treatment of 110.3 mg/L of methyl jasmonate for
two weeks. On the other hand, T. baccata showed the highest production of baccatin III
at 0.245% with treatment of 53.6 mg/L of methyl jasmonate for two weeks.30
Biosynthesis has further been studied in nodule cultures. The nodules are of optimal
composition for internal production of phytopharmaceuticals. The nodules were induced
from needles of various Taxus species. Nodule growth was encouraged though the
addition of sucrose. Higher levels of sucrose (0.5 to 1.0%) were associated with increased
paclitaxel production in T. cuspidata nodules. The yield for paclitaxel was approximately
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12 μg/g nodule. This was a unique approach to paclitaxel production but demonstrated no
advantages to methods already being utilized.31 More recently, researchers have been
exploring biotechnological sources for optimal paclitaxel production. A few of these
include plant cell cultures and expression systems.28
1.4 Drug Properties
Paclitaxel is a crystalline powder with a white to off-white coloration. The drug is
insoluble in water and is extremely lipophilic. It is administered intravenously due to its
low oral bioavailability. Taxol solution is a clear to yellow viscous liquid containing the
following per each mL: 6 mg paclitaxel, 527 mg of polyoxyethylated castor oil
(Cremophor EL), and 49.7% alcohol (v/v).7
1.4.1 Pharmacokinetics
Paclitaxel is 95% bound to plasma protein.32 This high level of binding affects the drug’s
rate of clearance. Taxol also demonstrates non-linear or dose-dependent disposition. This
is particularly evident when the drug is given with decreased infusion times (i.e., 3 hour).
Non-linear disposition indicates that there is a non-proportional relationship between
dose of the drug and the area under the curve (AUC) for the plasma concentration versus
time graph. With this disposition, changes in dosage cause a disproportionate degree of
change in the drug clearance, as well as AUC. This relationship is described by the
following equation:
Clearance=Dose/AUC
For linear pharmacokinetics, clearance is kept constant despite changes in dosage. The
non-linear pharmacokinetics demonstrated by Taxol can significantly affect the efficacy
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of the drug. Often, a change in dose results from increased patient side effects due to the
drug’s toxicity. A small change in dose can amount to significant changes in AUC and
clearance. Changes to clearance can impact the duration of the drug action, which may
have implications for the drug’s efficacy.33
The cause of the non-linear pharmacokinetic profile of Taxol has been studied and is
contributed to the Cremophor EL-ethanol vehicle. A similar compound, Docetaxel, is
formulated using Tween 80-ethanol. When paclitaxel is formulated using this vehicle, it
no longer demonstrates a non-linear disposition. Dimethylacetamine, a solvent commonly
used for low-solubility drugs, also demonstrated linear pharmacokinetics when combined
with paclitaxel.34
1.4.2 Metabolism
Paclitaxel is primarily metabolized by the liver via human cytochrome P450 2C8
hydroxylation. This metabolism forms the major metabolite 6-α-hydroxy- paclitaxel. The
drug is also metabolized by CYP3A4, forming a secondary metabolite, 3’-phydroxyphenyl-paclitaxel, also referred to as Metabolite B.35 6-α- hydroxy-paclitaxel
may be further metabolized by CYP3A4 to Metabolite A, also known as 6-α-hydroxy-3’p-hydroxyphenyl-paclitaxel.36 Since paclitaxel is predominantly metabolized through the
liver, it is reasonable to expect changes in elimination with hepatic dysfunction.
Therefore, treating patients who have hepatic dysfunction with paclitaxel may not be safe
at all doses. A safe dose for patients exhibiting severe hepatic dysfunction was
determined to be 70 mg/m2 every two weeks, with no change in maximum plasma
concentration from patients exhibiting normal hepatic function.37
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Renal clearance of paclitaxel is very minimal (14.3±1.4% of the total dose).38 Patients
with advanced urothelial carcinoma and renal insufficiency have been affectively treated
with paclitaxel.39 Patients exhibiting both conditions often do not have good options for
treatment. A phase II trial of paclitaxel and carboplatin also proved successful, with a
24.3% response rate for patients exhibiting urothelial carcinoma and renal dysfunction.40
1.4.3 Toxicity
Taxol administration can result in a range of toxicities. The most common toxicity is
neutropenia due to the drug’s ability to cause myelosuppression. The drug is
contraindicated for patients with neutrophil counts less than 1500 cells/mm3.7
Neutropenia is more common with longer infusion times of the drug.41 Peripheral
neuropathy occurs in about 60% of patients receiving Taxol. As dose increases, the
prevalence of neuropathy increases. Cardiovascular events are also possible but only
occur in 1% of patients receiving paclitaxel alone. When Taxol is combined with
cisplatin, incidence of cardiovascular events increases to 12-13% of patients. Neuropathy
may also become more prevalent in patients receiving this combination therapy. In a
phase III trial, hypersensitivity reactions occurred in 41% of all patients, even with
premedication. These reactions, as mentioned previously, are contributed to Cremophor
EL and provide the basis for discovery of a better drug delivery system.7
1.5 Delivery Systems
Cremophor EL toxicity has been a major issue with paclitaxel therapy. This formulation
has also been associated with leaching of di-(2-ethylhexyl)phthalate, a toxic material that
poses other health risks.42 Delivery systems that are void of Cremophor EL are desired to
ensure patient safety. There are many delivery systems that are currently being explored
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for paclitaxel to solve the issue of poor solubility and low permeability in vivo. A few of
these formulations include micelles, liposomes, nanoparticles, emulsions, lipid-based
delivery, solid dispersions, implants, oral tablets, etc. The two drugs synthesized and
discussed in this work are nanoparticle formulations.
Nanoparticles are structures consisting of polymers, lipids, inorganic molecules, and
other components that are submicron sized.44 There are many advantages to using a
nanoparticle formulation. A few advantages include increased accumulation of the drug
in tumor cells, increased bioavailability, and improved solubility.48 Nanoparticles can
also generate more targeted treatments through modification of the surface structure of
the particles.44
Abraxane is a paclitaxel-containing drug that reached the market in 2005.44 The drug
consists of nanoparticles prepared through homogenization of paclitaxel with human
serum albumin (HSA). Since this formulation does not include Cremophor EL, risks of
hypersensitivity reactions are diminished and leaching of plasticizing agents is no longer
an issue. Abraxane exhibits linear pharmacokinetics, and the presence of HSA enhances
tissue partition.49 Abraxane also has a much higher tolerable dose (300 mg/m2) verses
Taxol (175 mg/m2).42
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Paclitaxel Complexation with Copper and Iron

A novel paclitaxel drug consisting of copper and iron is synthesized and evaluated for
anticancer activity. The addition of metal cations to anticancer drugs has become
increasingly more common due to the redox potential of the metals offering a new
mechanism of action and eliminating issues surrounding cancer drug resistance. In this
instance, the properties of Fe3+ and Cu2+ are considered and activity of the cation-drug
complex is evaluated.
2.1 Medicinal Action
Reactive oxygen species (ROS) are highly reactive molecules that are essential for cell
signaling. Elevated levels of ROS create irreversible cellular damage and contribute to
cell proliferation and metastasis via angiogenesis promotion. Many cancer therapies use
an anti-oxidant strategy to eliminate the ROS that contribute to the promotion and
survival of tumor phenotypes. ROS, therefore, are oncogenic but they may also be
utilized to kill cancerous cells.61 ROS present in modest numbers are oncogenic in nature;
highly elevated levels of ROS function to suppress tumors.62 A pro-oxidant therapy
would generate free radicals, leading to oxidative stress and irreversible damage to tumor
cells. One pro-oxidant therapy strategy includes employing the combination of an ROSdependent anticancer agent with an ROS-producing agent. This approach may lead to an
increase in the therapeutic outcome of the treatment.63 It is already known that tumor
cells have an increased basal level of ROS present in their environment. Therefore, it
would be easier to reach a death-triggering threshold in tumor cells than in healthy cells.
Because of this, patients are at no increased risk of cellular damage with ROS
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combination therapy than with traditional therapies. Paclitaxel is considered an ROSdependent chemotherapeutic agent. The combination of paclitaxel with an ROSproducing agent is expected to have little effect on healthy cells in vivo.61
2.1.1 Addition of Copper
Copper is one of many essential nutrients required for normal cellular function. In serum,
copper is approximately 70% bound to ceruloplasmin.64 Small amounts of copper may
also bind to human serum albumin and α2-macroglobin in serum. Normal copper levels
in humans are around 1000 ng/mL (100 μg/dL).65 Altered copper metabolism results in
disorders which include Menkes disease and Wilson’s disease. Menkes disease results in
disrupted copper transport and decreased copper levels. Conversely, Wilson’s disease is
characterized by the failure to remove copper, resulting in the buildup of excess copper.
Copper also plays a role in other disorders such as Alzheimer’s disease and diabetes
mellitus and promotes angiogenesis.66 Many cancer types have shown elevated copper
levels including breast, lung, colon, prostate, and brain cancer.67 For patients with breast
cancer, the levels of copper indicate the severity of the disease process. Additionally,
ceruloplasmin levels are seen to increase by four to eight- fold during tumor cell
progression.68
The reduction-oxidation reactions of copper allow the ion to switch oxidation states
readily (Equations 1-3). Copper ions in the 1+ oxidation state then participate in Fentonlike reactions that produce ROS (Equation 4).69 Because of this redox behavior, copper is
a potential agent for the ROS-combination therapy previously described. In serum,
reduced copper (Cu+) can bind to the amine group of paclitaxel to form a Cu-N bond.
With copper already bound to the amine portion of the drug, this protects the amine from
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forming bonds with Cu ions in the environment and allows the drug to reach its target
site.70,71
Cu+ + e- ⇌ Cu(s)

Eo= +0.520 V

(1)

Cu2+ + 2e- ⇌ Cu(s)

Eo= +0.337 V

(2)

Cu2+ + e- ⇌ Cu+

Eo= +0.159 V

(3)

Cu+ + H2O2 →Cu2+ + •OH + OH-

(4)

2.1.2 Addition of Iron
Iron is an essential element responsible for DNA replication, repair, proper cellular
function and plays a role in oxygen-binding.72 Iron levels must be kept within certain
limits to avoid the effects of either iron deficiency or iron overload. At normal levels,
there is approximately 3-4 g of iron in the human body. Most of this iron is found within
hemoglobin (2-3 g).73 Iron can also be found in serum bound to the iron transport protein
transferrin, although normally only 0.1% of iron is bound by the protein. Once inside the
cell, iron can either be found in its stored form, ferritin, or in the labile iron pool. The
atoms found in the labile iron pool are active, unbound ions and when in excess, can
cause toxicity via oxidative stress.72
Iron homeostasis is controlled by many factors, two of which are the transporters divalent
metal transporter-1 (DMT-1) and ferroportin which control the flow of iron in and out of
the absorptive cells of the duodenum and of certain other cells. The ultimate iron
regulator is a protein secreted by the liver known as hepcidin.74 Hepcidin binds to
ferroportin to prevent iron absorption in the duodenum. Therefore, when iron levels
become elevated, hepcidin levels are elevated. Inflammatory conditions can also lead to
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an increased hepcidin level.75 When hepcidin remains at chronically low levels, this
causes complications of excess iron absorption and iron overload.76 Iron overload can
lead to a process known as ferroptosis, a form of controlled cell death contributed to iron
and ROS generation.77
Many of the iron receptors and transporters show changes that align with tumor cells’
demand for iron. For example, transferrin receptors are elevated in cancerous cells to
supply the tumor cells with more iron.78 In breast cancer cells, ferroportin levels were
shown to be decreased and hepcidin levels increased. This is likely due to iron retention
by the tumor cells. These patients also had a decrease in metastasis-free and diseasespecific survival.79 Ferritin levels have proven to be elevated in some tumor types.80 Each
of these examples demonstrate the increase in iron availability to tumor cells and an
increase in the active labile iron pool.74
The addition of iron in the cation-drug anticancer complex serves a few roles:
a) The iron acts as a nutrient that feeds the tumor cells. Since the iron is complexed with
the drug, the drug will be driven into the cell via iron acquisition. This is described as a
“Trojan Horse Effect”, as the drug is disguised through nutrient complexation.68
b) Iron contributes to the generation of reactive oxygen species that can damage cells and
result in ferroptosis. ROS at moderate levels promote a more aggressive phenotype.77
Addition of iron in the cation-drug complex would result in ROS levels of the tumor cells
exceeding optimal levels and ultimately result in cell death. Iron readily switches
oxidation states between Fe2+ and Fe4+ (Equations 5-7). ROS are then produced via
Fenton reactions (Equation 8).69
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Fe2+ + 2e- ⇌ Fe(s)

Eo= -0.44 V

(5)

Fe3+ + 3e- ⇌ Fe(s).

Eo= -0.04 V

(6)

Fe3+ + e- ⇌ Fe2+

Eo= +0.77 V

(7)

Fe2+ +H2O2 →Cu3+ + •OH + OH-

(8)

2.2 Methods
2.2.1 Drug Synthesis
The Cu5Fe5PAC drug is synthesized by reacting paclitaxel (C47H51NO14; MW: 853.91 g)
with 5 molar equivalents of copper (II) chloride dihydrate (CuCl2H4O2; MW: 170.48 g)
and iron (III) chloride hexahydrate (FeCl3H12O6; MW: 270.29 g). 15 mL of ethanol
(EtOH) was used to combine the components. An amount of 30 mg of paclitaxel (PAC)
was chosen for testing. Weighted amounts of CuCl2 and FeCl3 were then determined
based on molar calculations. The solution was allowed to stir for 24 hours. When allowed
to dry (over a 24 to 48-hour period), the drug will form a crystalline structure that can be
mechanically grinded into nanoparticles.
2.2.2 National Cancer Institute Data
The Development Therapeutics Program of the National Cancer Institute (NCI) offers
human tumor cell line screening that tests for growth inhibition and cell mortality of
potential medicinal agents against 60 different tumor cell lines. The cell lines include
tumor cells of the following nine cancer types: leukemia, non- small cell lung (NSCLC),
colon, central nervous system (CNS), melanoma, ovarian, renal, prostate and breast.
Information summarizing each cell line is included in Appendix A.
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Each medicinal agent that is tested in the sixty-cell line panel is first tested against a
select number of tumor cell lines at one single high dose (10-5 M) to evaluate if a predetermined antitumor activity threshold is met. Once this baseline antitumor activity is
established and the threshold is met, the agent then moves on to full testing. Full testing
includes utilizing all cell lines in the panel, as well as testing five different concentrations
of the medicinal agent (10-9, 10-8, 10-7, 10-6, 10-5) against each cell line for 48 hours.
The in vitro test results provided by the NCI include values for percent growth (per each
concentration), GI50, TGI and LC50. Percent growth (PG) values are determined by using
two different equations. The equations include values obtained from absorbance
measurements for number of cells at time zero (Tz), number of cells present when treated
with control (C), and number of cells in the presence of the medicinal agent at the five
concentrations (Ti). PG values from -100 to 0 indicate lethality and values from 0 to 100
indicate growth inhibition. The equations are as follows:
When Ti ≥ Tz, PG= (Ti-Tz)/(C-Tz) x 100

(9)

When Ti < Tz, PG= (Ti-Tz)/Tz x 100

(10)

The GI50 values indicate the concentration of the medicinal agent when the growth is
inhibited by half or 50%. The GI50 values are calculated using Equation 9 with PG=50.
TGI (total growth inhibition) values indicate the concentration that results in complete
inhibition of growth of the given tumor cell line. TGI is calculated using Tz=Ti. The LC50
value is defined as the concentration of the medicinal agent that results in death of half or
50% of the tumor cells of a given cell line. The LC50 value is calculated from Equation 10
with PG= -50.81
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2.3 Results
2.3.1 Analytical Testing
Various drug ratio compositions consisting of paclitaxel, copper, and iron were analyzed
using different techniques which include MALDI-TOF-MS, 1H-NMR, and FT-IR. The
MALDI-TOF-MS is located in the proteomics and mass spectrometry (PAMS) facility at
the University of Georgia. Spectra were obtained for pure paclitaxel (Figure 2.1),
Cu5Paclitaxel (Figure 2.2) and Fe5Paclitaxel (Figure 2.3). Combining information from
the spectra analyzed gives predictions for the behavior of the Cu5Fe5PAC drug.

Figure 2.1.

MALDI-TOF-MS spectrum of paclitaxel.

All MALDI-TOF spectra obtained are shown to have both sodium (Na) and potassium
(K) adducts present, which are common background ions. Figure 2.1 displays the
spectrum for pure paclitaxel, with peaks for paclitaxel (m/z= 854), paclitaxel + Na
(m/z=877), and paclitaxel + K (m/z=893). The spectrum of Cu5PAC in Figure 2.2 shows
the same peaks as mentioned (m/z= 854, 877, and 893), as well as a peak for paclitaxel +
Cu (m/z= 917). This indicates that in the Cu5Paclitaxel drug, a single metal ion survived
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the ionization process required for MALDI-TOF testing. Figure 2.3 contains the spectrum
for Fe5PAC. The spectrum displays peaks for paclitaxel alone, PAC + Na and PAC + K
as with the other samples. With this drug (Fe5Paclitaxel), we see that two metal ions were
able to survive the ionization process. This is shown by a peak for paclitaxel + Fe (m/z=
909) and paclitaxel + 2Fe + Na (m/z= 989).

Figure 2.2.

MALDI-TOF-MS spectrum of Cu5Paclitaxel.

Figure 2.3.

MALDI-TOF-MS spectrum of Fe5Paclitaxel.

The 600 MHz NMR spectrometer used for testing is located in the chemistry department
at Texas A&M University. The 1H-NMR spectra were obtained for pure paclitaxel,
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Cu5Paclitaxel and Fe5Paclitaxel. Figure 2.4 shows paclitaxel with all hydrogens labeled
and is used for analysis of the NMR spectra. The NMR spectrum of pure paclitaxel is
shown in Figure 2.5. The spectrum is evaluated by comparing to 1H assignments
previously published.82 A table was created to compare the shifts observed on the NMR
spectrum for paclitaxel to the shifts expected from those published (Table 2.1). The
addition of copper to the drug has very little effect on the spectrum (Cu5PAC; Figure
2.6). This leads one to believe that copper may not have an interaction with the drug.
However, MALDI-TOF showed a clear interaction between copper and paclitaxel. This
behavior with copper complexation has been observed in other studies.83 The shifts for
the Cu5Paclitaxel drug are compared to those seen in pure paclitaxel in Table B.1. The
slight change in shifts and loss of coupling patterns is due to the mild broadening effect
of the copper ions. Figure 2.7 shows the spectrum for the Fe5Paclitaxel drug. A very
different effect is seen with the addition of iron to the drug. The observed peaks are
significantly relaxed as compared to pure paclitaxel and Cu5Paclitaxel. The relaxed state
is due to dipole magnetic coupling fluctuations associated with Fe3+. This relaxation is
associated with Fe3+ and its paramagnetic behavior caused by the number of valence
electrons (five) with unpaired spins, creating a magnetic field which interacts with the
NMR machinery.
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Figure 2.4.

Paclitaxel molecule with H’s and H-containing moieties labeled.

Figure 2.5.

1

H-NMR spectrum of paclitaxel.
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Table 2.1.

1

Assignment
H1
H2, H6
H3, H5
H4
H7
H8-H10
H11
H12
H13
H14
H15
H16
H17-H19
H20
H21-H23
H24
H25
H26
H27, H31
H28, H30
H29
H32, H36
H33, H35
H34
H37
H38
H39-H41
H42-H44
H45-H47
OH1
OH2
OH3
NH1

H-NMR assignments for paclitaxel in CDCl3.

Shift (observed)
5.6907
8.1814
7.5555
7.6744
3.8418
2.4318
4.3201
4.2092
4.9912
2.5477
1.8546
4.4413
1.6807
6.3022
2.2301
6.2625
4.8357
5.8081
7.7790
7.4367
7.4828
7.4664
7.4519
7.3969
2.3995
2.3045
1.8215
1.2694
1.1658
2.4825
3.6591
1.9728
7.0672

Shift (expected)*
5.67
8.13
7.51
7.61
3.79
2.38
4.30
4.19
4.94
2.54
1.88
4.40
1.68
6.27
2.23
6.23
4.78
5.78
7.74
7.40
7.49
7.48
7.42
7.35
2.35
2.28
1.79
1.24
1.14
2.48
3.61
1.98
7.01

Multiplicity
d
dd
cm
tt
d
s
d
dd
dd
ddd
ddd
dd
s
s
s
td
s
dd
dd
cm
cm
cm
cm
tt
dd
dd
d
s
s
bs
bs
bs
d

*Values from Chmurny, et al.82

FT-IR was used to analyze and compare pure paclitaxel to the Cu5Fe5PAC drug. Spectra
for each formulation was collected between the frequencies of 600-4000 cm-1. The
samples were in their dry crystalline form for testing. Figure 2.8 shows the spectrum for
pure paclitaxel. The spectrum obtained is compared to results previously published. The
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peaks correspond to the following bond stretching vibrations: N-H stretching at 3469 cm1

; CH2 symmetrical and asymmetrical stretching at 2888 and 2932 cm-1; C=O stretching

of ester at 1729 and 1715 cm-1; amide stretching at 1632 cm-1; ester stretching at 1251
cm-1; and C-N stretching at 1273 cm-1. Peaks are also identified at 1072 and 707 cm-1
which correspond to C-H aromatic bonds in the structure and are considered fingerprint
for identification of paclitaxel. Additional peaks at ~1604 and ~943 are contributed to
C=C and C-H aromatic bonds respectively and are not labeled in the figure.84 Figure 2.9
shows the spectrum of the Cu5Fe5Paclitaxel drug. The C-H aromatic bond peaks in the
fingerprint region (1072 and 707 cm-1) remain present on the spectrum. Ester stretching at
1251 cm-1 is also evident. Although the frequency of the bonds mentioned have not
changed, the percent transmittance (%T) of each bond increased by a factor of 20. This
indicates that less of these bonds were absorbed for the Cu5Fe5Paclitaxel drug, although
paclitaxel concentrations in each sample are the same. In the Cu5Fe5PAC drug, the C=O
ester and amide stretching is replaced by a singular peak at 1624 cm-1. This peak is
thought to be contributed to a Fe-carbonyl (COO-Fe) bond as described in a study using
FeCl3.85 The interaction of copper with paclitaxel falls outside of the range of the FTIR
instrument. Copper is predicted to form a C-N bond with the amine portion of paclitaxel.
This would fall in the 500-600 cm-1 range.86 Another possible bond between paclitaxel
and copper is a Cu-O bond. This bond is also outside of the testing range, with peaks
being present between 400-600 cm-1.87
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Figure 2.6.

1

Figure 2.7.

1

H-NMR spectrum of Cu5Paclitaxel.

H-NMR spectrum of Fe5Paclitaxel.

Figure 2.8.

FT-IR spectrum of paclitaxel with major peaks labeled.
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Figure 2.9.

FT-IR spectrum of Cu5Fe5Paclitaxel with major peaks labeled.
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2.3.2 National Cancer Institute Data
The NCI data for the Cu5Fe5PAC drug is compared to that of pure paclitaxel (PAC). Data
for PAC was obtained using the NCI COMPARE database. Table 2.2 contains logarithm
scale values for GI50, LC50 and TGI values for Cu5Fe5PAC and PAC. Full NCI data for
each drug can be found in Appendix B and Appendix D respectively. The NCI denotes
significance values for the LogGI50 concentration, with -8.0 being for the smallest
concentration and -5.0 being the largest concentration. Therefore, a value of -8.0 could
denote a concentration that is -8.0 or smaller.
The PAC GI50 data ranges from -8.0 (smallest concentration) to -5.54 (largest
concentration), whereas Cu5Fe5PAC ranges from -8.0 to -4.48. PAC contains 39 cell lines
with a LogGI50 of ≤ -8.0 out of 60 tested. The Cu5Fe5PAC drug only contains 8 cell lines
at this concentration with only 48 cell lines available to be tested. An average LogGI50
concentration among all cell lines was determined for each drug with PAC having an
average inhibitory concentration of -7.71 and Cu5Fe5PAC having an average inhibitory
concentration of -7.38. A two-sample z- test was used to determine if the values are
significantly different between the two drugs. A confidence interval of 95% was utilized.
The results indicated a significant difference in values between the two drugs (p-value=
0.041), demonstrating that PAC has an advantage over Cu5Fe5PAC in its cytostatic
ability.
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Table 2.2.

Comparison of logarithm values of GI50, LC50 and TGI for PAC versus
Cu5Fe5PAC.
PAC

Cell Line
Leukemia
CCRF-CEM
HL-60(TB)
K-562
MOLT-4
RPMI-8226
SR
NSCLC
A549/ATCC
EKVX
HOP-62
HOP-92
NCI-H226
NCI-H23
NCI-H322M
NCI-H460
NCI-H522
Colon
COLO 205
HCC-2998
HCT-116
HCT-15
HT29
KM12
SW-620
CNS
SF-268
SF-295
SF-539
SNB-19
SNB-75
U251
Melanoma
LOX IMVI
MALME-3M
M14
MDA-MB-435

Log10GI50
(M)

Cu5Fe5PAC Drug

Log10LC50

Log10TGI

-8.00
-8.00
-8.00
-8.00
-8.00
-8.00

-4.60
-4.63
-4.60
-4.60
-4.60
-4.60

-4.99
-7.38
-4.85
-5.12
-5.65
-5.37

-8.00
-7.17
-7.91
-6.99
-7.20
-8.00
-7.98
-8.00
-8.00

-4.60
-4.60
-4.60
-4.60
-4.60
-4.60
-4.60
-4.60
-4.60

-8.00
-8.00
-8.00
-6.79
-8.00
-8.00
-8.00

Log10GI50
(M)

Log10LC50

Log10TGI

-7.87
-7.96
-7.90
-7.32
-7.89
-8.00

-4.48
-4.48
-4.48
-4.48
-4.48
-4.48

-4.48
-4.48
-4.48
-4.48
-4.48
-4.48

-4.60
-4.62
-5.24
-5.13
-5.03
-5.50
-5.04
-4.68
-6.61

-7.63
-6.59
-7.00
-4.48
---7.65
-7.85
-7.97
-7.95

-4.48
-4.48
-4.48
-4.48
-4.48
-4.48
-4.48
-4.48
-4.48

-4.48
-4.48
-4.48
-4.48
-4.48
-4.48
-4.48
-4.48
-4.48

-4.90
-5.17
-4.60
-4.65
-4.76
-4.60
-4.60

-6.45
-6.89
-4.74
-4.77
-6.60
-4.78
-4.60

---7.91
-8.00
-6.24
-8.00
-7.92
-7.77

---4.48
-4.48
-4.48
-4.48
-4.48
-4.48

---4.48
-4.48
-4.48
-4.60
-4.48
-4.48

-8.00
-7.92
-8.00
-8.00
-8.00
-8.00

-4.60
-4.63
-5.04
-4.60
-4.60
-4.60

-4.62
-6.31
-7.40
-4.65
-6.90
-5.04

---7.33
-8.00
-7.57
-8.00
-7.83

-4.48
-4.48
-4.48
-4.48
-4.48
-4.48

-4.48
-4.48
---4.48
---4.48

-8.00
-7.44
-8.00
-8.00

-4.62
-4.60
-4.60
-4.60

-4.84
-4.78
-5.94
-8.09

-7.97
---7.90
-8.00

-4.48
-4.48
-4.48
---

-4.48
-4.48
-----

(cont. on next page)
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Table 2.2 (cont.)
SK-MEL-2
SK-MEL-28
SK-MEL-5
UACC-257
UACC-62
Ovarian
IGROV1
OVCAR-3
OVCAR-4
OVCAR-5
OVCAR-8
NCI-ADR-RES
SK-OV-3
Renal
786-0
A498
ACHN
CAKI-1
RXF 393
SN12C
TK-10
UO-31
Prostate
PC-3
DU-145
Breast
MCF7
MDA-MB231/ATCC
HS 578T
BT-549
T-47D
MDA-MB-468

-7.68
-7.33
-8.00
-7.66
-8.00

-4.60
-4.60
-4.60
-4.60
-4.62

-5.02
-4.60
-5.01
-4.64
-4.97

---4.48
-7.32
-----

-4.48
-4.48
-4.48
-4.48
-4.48

-4.48
-4.48
-4.48
-4.48
-4.48

-8.00
-8.00
-6.26
-7.41
-8.00
-5.54
-8.00

-4.60
-4.84
-4.60
-4.60
-4.60
-4.61
-4.60

-4.77
-7.40
-4.72
-5.28
-4.66
-4.80
-4.78

-7.83
-7.95
-4.48
-7.79
-7.62
-5.42
---

-4.48
-4.48
-4.48
-4.48
-4.48
-4.48
---

-4.48
-4.48
-4.48
-4.48
-4.48
-4.48
---

-7.88
-7.23
-6.34
-6.66
-8.00
-8.00
-7.54
-5.99

-4.61
-4.60
-4.60
-4.60
-4.60
-4.60
-4.60
-4.60

-4.65
-4.75
-4.80
-4.87
-6.37
-4.75
-5.53
-4.71

-----6.09
---7.68
---6.68
-6.27

-4.48
---4.48
-4.48
---4.48
-4.48
-4.48

-4.48
---4.48
-4.48
---4.48
-4.48
-4.48

-8.00
-8.00

-4.60
-4.77

-4.93
-6.53

-7.86
-7.94

-4.48
-4.48

-4.48
-7.27

-8.00
-8.00

-4.60
-4.60

-4.82
-5.17

-8.00
-7.64

-4.48
-4.48

-4.48
-4.48

-8.00
-8.00
-7.49
-8.00

-7.75
-4.60
-4.60
-4.62

-7.08
-5.92
-4.60
-5.85

-8.00
---7.58
-7.96

---4.48
-4.48
-4.48

---4.48
-4.48
-4.48

The LC50 data demonstrates the cytotoxic ability of the drugs. The major Log10LC50
concentrations of PAC and Cu5Fe5PAC have a smaller range than the GI50 values. The
PAC values range from -7.75 to -4.6, with the latter concentration correlated with 45 of
the 60 cell lines tested. All 54 cell lines tested for Cu5Fe5PAC display a concentration of 4.48. The average value for PAC is -4.69 whereas the average value for Cu5Fe5PAC is -
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4.48. The same parameters mentioned previously were utilized for the two-sample z-test.
Results demonstrate that the two data sets are significantly different (p-value= 1.00 x 104

). PAC, therefore, is more successful than Cu5Fe5PAC in its cytotoxic abilities as well.

The TGI value indicates a total inhibitory concentration for the drugs. The Log10TGI
values between PAC and Cu5Fe5PAC vary. PAC shows more variation in values, with a
range from -8.09 to -4.6, with many values in between. The average concentration for
PAC is -5.39. Cu5Fe5PAC has less variation, exhibiting a range from -7.27 to -4.48, with
49 of the total 51 cell lines tested having a concentration of -4.48. The average LogTGI
concentration for this drug is -4.54. A two-sample z-test was completed as described. The
results demonstrate that the values are significantly different between the two drugs (pvalue= 3.35 x 10-11).
Based on the NCI in vitro data, pure paclitaxel is overall more successful at both partial
and total growth inhibition and cell line mortality than Cu5Fe5PAC. However, the
Cu5Fe5PAC nanoparticles have advantages over pure paclitaxel, including the unique
mechanism of action. In vivo testing is necessary to determine how well treatment with
the Cu5Fe5PAC drug truly compares to that of PAC and to determine if the new drug
offers an advantage over current PAC therapy.
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Paclitaxel Complexation with Copper, Glucose, and Albumin

A drug containing copper complexed to paclitaxel, denatured human serum albumin, and
glucose is synthesized and tested for anti-cancer activity. Each component added
increases in drug activity in vivo.
3.1 Medicinal Action
3.1.1 Addition of Glucose
Tumor cells rely on a constant supply of energy and nutrients to continue to grow and
proliferate. These cells undergo an altered metabolic process that is known as the
“Warburg Effect”. This process confers a switch from oxidative phosphorylation to
glycolysis. This switch seems to be counter-productive since it results in less efficient
energy production. However, this altered metabolism is necessary to produce the needed
metabolic end products to support the rapid growth of tumor cells and the energy
expenditure associated with immune system activation.88
The change to glycolysis is controlled by the mutations that resulted in the cancerous
state and is necessary for survival of the tumor cells. The metabolic changes offer a clear
advantage to the tumor cells. Studies have shown tumor cells that switch back to
undergoing oxidative phosphorylation grew less and had less tumorgenicity.89
The switch away from oxidative phosphorylation has little to do with the oxygen levels
present in the tumor environment. It has been observed that this switch occurs regardless
of oxygen being present in high or low levels.90 Studies have revealed the genetic
changes that confer this switch. The increased glycolysis is thought to be the result of
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increased activation of HIF (hypoxia-inducible factor). The additional expression of this
factor results in increased expression of all glycolytic enzymes.89 Additionally, glucose
transporters, specifically GLUT1 and GLUT3, become overexpressed because of
HIF.88,89 HIF-1 also downregulates the TCA cycle which blocks the conversion of
pyruvate to acetyl-CoA. This results in the conversion of pyruvate to lactate by lactate
dehydrogenase (an enzyme that is upregulated by HIF) and the generation of NAD+ that
can feed back into glycolysis.89
Overexpression of GLUT1 transporters has been observed in the following cancers:
brain, renal, lung, cutaneous, colorectal, esophageal, breast, pancreatic, hepatic,
endometrial, ovarian, and cervical.91 The addition of glucose to the paclitaxel complex
aims to exploit these transporters by driving the drug into the cell. Complexation of the
medicinal agent to glucose disguises the drug as a nutrient and allows for its uptake. This
is known as the "Trojan Horse Effect."
3.1.2 Addition of Albumin
Albumin is the most prominent protein in the blood and has a long circulation life.92 It
has a molecular weight of about 67 kDA and is present at a concentration of 40 mg/mL of
blood.93 Drug complexation with albumin results in many advantages. Albumin has the
ability to prolong the serum lifetime of drugs that are typically fast-clearing and/or
hydrophobic. The protein also possesses unique properties that allow for its accumulation
at tumor sites. It is also noted that albumin plays a role in the solubilization and transport
of copper after absorption.92
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Albumin has the ability to accumulate at tumors due to tumor vasculature leakiness and
poor lymphatic drainage at the site. This phenomenon is known as the enhanced
permeability and retention effect (EPR).92
Abraxane, a paclitaxel drug mentioned in Section 1.5, contains paclitaxel that is bound to
albumin. The drug, also known as nanoparticle albumin-bound paclitaxel (nabpaclitaxel), offers increased solubility, longer half-life, and elimination of pretreatment
that is required for administration of paclitaxel in Cremophor-EL.49
3.2 Methods
3.2.1 Drug Synthesis
The (CUPAC)5GLU12DALB (CPGD) drug is synthesized by reacting paclitaxel
(C46H51NO14; MW: 853.91 g) with one molar equivalent copper (II) chloride dihydrate
(CuCl2H4O2; MW: 170.48 g). This is then combined in a 5:1 ratio with one molar
equivalent of denatured albumin (C123H193N35O37; MW: 66430.3 g) glycated with 12
molar equivalents of glucose (C6H12O6; MW: 180.156 g). To denature the protein, the
albumin is gently heated in a 70:30 ratio of ethanol to water. 10 ppm of silver chloride
(AgCl) was added before heating to 50-60°C (122-140°F).94 A total of 15 mL of ethanol
was used to combine the drug components. After combining all components, the drug
was allowed to stir for 24 hours. Drying the liquid for 24-48 hours yields a crystalline
drug that is mechanically grinded down to nanoparticles.
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3.3 Results
3.3.1 Analytical Testing
MALDI-TOF-MS and 1H-NMR was evaluated for the following: albumin; denatured
albumin; denatured albumin with copper; albumin with paclitaxel; and denatured albumin
with copper and paclitaxel. It is important to note that the large size of the albumin
molecule limits the ability to interpret the MS spectra due to relaxation and broadening of
signals.
Figure 3.1 contains the MALDI-TOF-MS spectrum of albumin and albumin after the
denaturation process. Both have a relative peak mass of about 67,000 Da. Comparison the
two spectra show that the denaturation process does not increase the mass of the albumin.
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Figure 3.1.

MALDI-TOF-MS of: A. Human serum albumin and B. Denatured human serum
albumin.

Figure 3.2 contains the spectrum for denatured albumin and copper. The spectrum is
compared to that of denatured albumin alone (Figure 3.1b). A strong interaction can be
seen with the addition of copper, which is indicated by the significant spectral changes. A
single broad peak is shown at a m/z of about 86,447.
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Figure 3.2.

MALDI-TOF-MS of denatured albumin and copper.

The spectrum of albumin with paclitaxel is shown in Figure 3.3. This is compared to the
spectra of albumin alone (both untreated and denatured; Figure 3.1). All spectra display
signature peaks in the same mass range, indicating that paclitaxel has no interaction with
the protein in either form.
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Figure 3.3.

MALDI-TOF-MS of albumin and paclitaxel.

The last spectrum contains denatured albumin with copper and paclitaxel, shown in
Figure 3.4. The copper and paclitaxel are complexed before addition of the denatured
albumin. The spectrum shows a unique set of peaks that are not seen with denatured
albumin and copper (Figure 3.2) or albumin and paclitaxel (Figure 3.3). As previously
mentioned, copper has an affinity for binding amines, which is one possible scenario for
binding to albumin. Copper also has an affinity for binding sulfur ions present in the
amino acid residues of albumin.95 The structure following this binding is likely a very
complex, entwined aggregate.
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Figure 3.4.

MALDI-TOF-MS of denatured albumin, paclitaxel, and copper.

The NMR spectra reiterate the findings of the MALDI-TOF spectra. Figure 3.5 compares
the spectra of DALB and DALB with copper. Clear changes can be seen between the two
spectra which indicates an interaction between the DALB and the copper. Figure 3.6
contains the spectra for albumin and albumin with paclitaxel. The two spectra have a very
close resemblance, demonstrating that paclitaxel has no interaction with albumin. This is
important to note since a common paclitaxel-containing drug, Abraxane (nab-paclitaxel),
contains paclitaxel wrapped in an albumin shell. The spectra indicate that in the
(CUPAC)5GLU12DALB drug no interaction between the drug and the protein occurs until
paclitaxel is first complexed with copper. This is shown in Figure 3.7.
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Figure 3.5.

1

H-NMR spectrum of A. DALB and B. DALB and copper.
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Figure 3.6.

1

H-NMR spectrum of A. Albumin and B. Albumin and paclitaxel.

Figure 3.7.

1

H-NMR spectrum of DALB, copper, and paclitaxel.
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FT-IR was used to analyze and compare the following: paclitaxel; paclitaxel and copper;
paclitaxel, copper, and denatured albumin; and the CPDG drug (copper, paclitaxel,
glucose, and denatured albumin). Samples were in their dry crystalline form for testing.
Each spectrum was obtained over a frequency of 600-4000 cm-1. Figure 3.8 compares all
spectra obtained. Details regarding peaks on the IR spectrum of paclitaxel is discussed in
Section 2.3.1. The peaks that are present for paclitaxel are also seen in the copperpaclitaxel spectrum along with other mild spectral changes. The addition of DALB
results in clear spectral changes (Figure 3.8c). The band broadening seen is likely the
result of interaction between the DALB and copper-paclitaxel. This spectrum is
compared to the known spectrum of human serum albumin. Known bond peaks for
albumin at 2850, 2916, and 1586 cm-1 can be seen in the copper, paclitaxel and DALB
spectrum.96 These same peaks can be seen in the CPGD spectrum (Figure 3.8d) along
with the major peaks seen in paclitaxel and copper-paclitaxel.

Figure 3.8.

FT-IR spectrum of A. Paclitaxel; B. Paclitaxel and copper; C. Paclitaxel, copper
and DALB; and D. Paclitaxel, copper, glucose, and DALB.

44
3.3.2 National Cancer Institute Data
The NCI data for the (CUPAC)5GLU12DALB is compared to that of pure paclitaxel.
Table 3.1 summarizes the logarithm scale values for GI50, LC50, and TGI for CPGD and
PAC. Full NCI data is found in Appendix C and Appendix D respectively. For both pure
PAC and CPGD, all 60 cell lines were available for testing. The significance values are 8.0 (10-8) as the smallest concentration and the -5.0 (10-5) as the largest concentration.

Table 3.1.

Comparison of logarithm values of GI50, LC50 and TGI for PAC versus CPGD.
PAC

Cell Line
Leukemia
CCRF-CEM
HL-60(TB)
K-562
MOLT-4
RPMI-8226
SR
NSCLC
A549/ATCC
EKVX
HOP-62
HOP-92
NCI-H226
NCI-H23
NCI-H322M
NCI-H460
NCI-H522
Colon
COLO 205
HCC-2998
HCT-116
HCT-15
HT29
KM12
SW-620

(CUPAC)5(GLU)12-DALB

Log10GI50
(M)

Log10LC50

Log10TGI

Log10GI50
(M)

Log10LC50

Log10TGI

-8.00
-8.00
-8.00
-8.00
-8.00
-8.00

-4.60
-4.63
-4.60
-4.60
-4.60
-4.60

-4.99
-7.38
-4.85
-5.12
-5.65
-5.37

-6.84
-7.38
-7.07
-6.64
-7.32
-7.25

-5.00
-5.00
-5.00
-5.00
-5.00
-5.00

-5.00
-5.05
-5.00
-5.00
-5.00
-5.00

-8.00
-7.17
-7.91
-6.99
-7.20
-8.00
-7.98
-8.00
-8.00

-4.60
-4.60
-4.60
-4.60
-4.60
-4.60
-4.60
-4.60
-4.60

-4.60
-4.62
-5.24
-5.13
-5.03
-5.50
-5.04
-4.68
-6.61

-6.86
-6.04
-6.56
-5.00
-5.00
-6.62
-6.78
-7.41
-7.35

-5.00
-5.00
-5.00
-5.00
-5.00
-5.00
-5.00
-5.00
-5.00

-5.00
-5.00
-5.00
-5.00
-5.00
-5.00
-5.00
-5.00
-5.00

-8.00
-8.00
-8.00
-6.79
-8.00
-8.00
-8.00

-4.90
-5.17
-4.60
-4.65
-4.76
-4.60
-4.60

-6.45
-6.89
-4.74
-4.77
-6.60
-4.78
-4.60

-7.05
-6.94
-7.33
-5.34
-7.37
-7.37
-7.20

-5.00
-5.00
-5.00
-5.00
-5.00
-5.00
-5.00

-5.03
-6.15
-5.00
-5.00
-5.00
-5.00
-5.00

(cont. on next page)
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CNS
SF-268
SF-295
SF-539
SNB-19
SNB-75
U251
Melanoma
LOX IMVI
MALME-3M
M14
MDA-MB-435
SK-MEL-2
SK-MEL-28
SK-MEL-5
UACC-257
UACC-62
Ovarian
IGROV1
OVCAR-3
OVCAR-4
OVCAR-5
OVCAR-8
NCI-ADR-RES
SK-OV-3
Renal
786-0
A498
ACHN
CAKI-1
RXF 393
SN12C
TK-10
UO-31
Prostate
PC-3
DU-145
Breast
MCF7
MDA-MB-231/ATCC
HS 578T
BT-549
T-47D
MDA-MB-468

-8.00
-7.92
-8.00
-8.00
-8.00
-8.00

-4.60
-4.63
-5.04
-4.60
-4.60
-4.60

-4.62
-6.31
-7.40
-4.65
-6.90
-5.04

-6.72
-6.43
-6.90
-6.51
-6.50
-6.82

-5.00
-5.00
-5.00
-5.00
-5.00
-5.00

-5.00
-5.00
-6.20
-5.00
-6.45
-5.00

-8.00
-7.44
-8.00
-8.00
-7.68
-7.33
-8.00
-7.66
-8.00

-4.62
-4.60
-4.60
-4.60
-4.60
-4.60
-4.60
-4.60
-4.62

-4.84
-4.78
-5.94
-8.09
-5.02
-4.60
-5.01
-4.64
-4.97

-7.03
-6.40
-6.58
-7.66
-6.38
-5.08
-6.67
-5.46
-6.61

-5.00
-5.00
-5.00
-6.33
-5.00
-5.00
-5.00
-5.00
-5.00

-5.00
-5.00
-5.00
-7.27
-5.00
-5.00
-5.00
-5.00
-5.00

-8.00
-8.00
-6.26
-7.41
-8.00
-5.54
-8.00

-4.60
-4.84
-4.60
-4.60
-4.60
-4.61
-4.60

-4.77
-7.40
-4.72
-5.28
-4.66
-4.80
-4.78

-6.81
-7.39
-5.00
-6.89
-6.81
-5.00
-6.77

-5.00
-5.00
-5.00
-5.00
-5.00
-5.00
-5.00

-5.00
-5.55
-5.00
-5.00
-5.00
-5.00
-5.00

-7.88
-7.23
-6.34
-6.66
-8.00
-8.00
-7.54
-5.99

-4.61
-4.60
-4.60
-4.60
-4.60
-4.60
-4.60
-4.60

-4.65
-4.75
-4.80
-4.87
-6.37
-4.75
-5.53
-4.71

-5.78
-6.50
-5.00
-6.19
-7.03
-6.43
-5.00
-5.00

-5.00
-5.00
-5.00
-5.00
-5.00
-5.00
-5.00
-5.00

-5.00
-5.00
-5.00
-5.00
-6.26
-5.00
-5.00
-5.00

-8.00
-8.00

-4.60
-4.77

-4.93
-6.53

-6.87
-7.19

-5.00
-5.00

-5.00
-5.76

-8.00
-8.00
-8.00
-8.00
-7.49
-8.00

-4.60
-4.60
-7.75
-4.60
-4.60
-4.62

-4.82
-5.17
-7.08
-5.92
-4.60
-5.85

-7.34
-6.38
-7.38
-6.15
-6.56
-7.50

-5.00
-5.00
-5.00
-5.00
-5.00
-5.00

-5.00
-5.00
-6.54
-5.00
-5.00
-6.73
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The first parameter compared is the LogGI50 values. The PAC data has a range of
concentrations between -8 to -5.54 and contains 39 cell lines with a value of -8.0,
indicating a low concentration of the drug needed to inhibit cell growth. The CPGD drug
has a range between -7.66 to -5 and no values at -8.0. This alone suggests that the drug
does not perform as well as pure PAC. The average cell line inhibitory values are -7.75
for PAC and -6.63 for CPGD. Of all drugs (including Cu5Fe5PAC), CPGD performed the
worst at half cell line inhibition. A two-sample z-test was used to determine if the values
are significantly different between PAC and CPGD. Results indicate a significant
difference in values between the two drugs (p-value= 4.99 x 10-21). Pure PAC is the best
of all three drugs at inhibiting 50% of cells in the cell lines.
The next parameter evaluated is the LogLC50 values. PAC has LC50 values ranging from 7.75 to -4.6 with an average of -4.69. CPGD has one cell line with a concentration of 6.33 and the other 59 cell lines have a concentration of -5. The average value for CPGD
is -5.02. The average concentration value for CPGD is significantly less than for pure
PAC. Z-test results indicate a significant difference between the values of the two drugs
(p-value= 5.84 x 10-9). This indicates that CPGD is more successful than PAC at causing
cell line mortality. Clearly, this also indicates that CPGD is a much better cytotoxic agent
than Cu5Fe5PAC as well.
The last parameter compared for PAC and CPGD is the LogTGI values. The values for
PAC range from -8.09 to -4.6 with an average concentration of -5.39. CPGD values range
from -7.2 to -5, with 48 cell lines having the latter value. The average concentration for
CPGD is -5.20. Z-test results indicate that the TGI values for PAC and CPGD are not
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significantly different (p-value= 0.171). This indicates that the total inhibitory
concentrations of both drugs are considered equivalent.
The NCI sixty cell line panel results indicate that TGI values for CPGD are comparable
to PAC and that the drug is a better option than PAC in terms of cytotoxic ability, as
revealed by the LC50 data. The cell line panel only shows the drug’s capabilities in vitro.
Testing must be completed to obtain in vivo data to determine the full efficacy of CPGD
and understand how the drug compares to PAC.
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Inhaled Chemotherapy for Lung Cancer Treatment
Lung cancer has the highest mortality of any type of cancer worldwide. In 2018, 218,520
new cases of lung cancer were diagnosed and 142,080 people living with the condition
died. Lung cancer only has a five-year survival rate of 23%.97 One reason for the low
survival rate is that many patients are not diagnosed until the cancer is advanced or has
metastasized to other organs. For patients with localized lung cancer, the first option is
typically surgical removal of the tumor. There are instances where surgery is not feasible
and, in these cases, chemotherapy is required for treatment. Chemotherapy is most
commonly given via intravenous infusion. For patients having cancer only in the
pulmonary region, this can require administration of high doses of the drug to reach a
therapeutic concentration at the tumor site. With this high concentration of drug, many
patients experience unwanted side effects due to drug toxicity. Local drug delivery
presents a desirable option for lung cancer treatment. A more direct drug application will
result in a decreased dose being administered and will likely help with patient
compliance.98 Currently, there is limited research regarding the safety and efficacy of
inhaled chemotherapy treatments. There are many factors to be considered during inhaled
therapy which are discussed in this chapter.
4.1 Pulmonary Processes and Drug Considerations
4.1.1 Drug Deposition in Lungs
The first step to successful aerosol administration is deposition of the drug product into
the lungs. Factors must be considered such as anatomy of the lungs, aerodynamic
diameter, and drug properties. The lungs are divided into conducting zones and
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respiratory zones. The conducting zones are the central, larger airways that consist of the
trachea, two bronchi, and bronchioles. The respiratory zones are more peripheral and
include the respiratory bronchioles and the alveoli (ducts and sacs).98,99 There are three
methods for particle deposition: inertial impaction, gravitational sedimentation, and
diffusion. The drug particle's aerodynamic diameter indicates where and how the particle
can deposit along the airways. The formula for determining aerodynamic diameter is
shown in Equation 11, with Da being aerodynamic diameter, Dg being geometric
diameter, ⍴ being density, ⍴o being unit particle density, and S being dynamic shape
factor of the particle.98
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Different drug particles with the same aerodynamic diameter will reach the same velocity
along the airway regardless of particle density.98 Particles with a larger aerodynamic
diameter (>5 μm) are too large to change their trajectory and are succumbed to inertial
impaction in the conducting zones of the lungs.100 Particles with an aerodynamic
diameter between 1-5 μm can travel deeper into the airway and mostly deposit via
gravitational sedimentation. The smallest particles with an aerodynamic diameter of <1
μm deposit primarily by diffusion but are likely to remain in the airway and be
exhaled.101 However, it has been shown that particles with an actual diameter of less than
or equal to 500 nm (also called ultrafine particles) show an increase in deposition.102
Particles with a larger aerodynamic diameter are not suitable for lung cancers that are
located deeper within the lungs. Some of these particles, if inhaled using a device
requiring respiratory performance of the patient, may be caught in the mouth and throat
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area and are likely to become swallowed instead of reaching the lungs.99,103 For smaller
particles that may not deposit well, deposition may be increased by holding in the breath
following inhalation.104 Regardless of aerodynamic diameter, drug products that are
inhaled more slowly can deposit further along with airway. Similarly, particles that are
inhaled more quickly deposit more in the central conducting zones of the lungs.99
4.1.2 Surface Contact/Dissolution
Deposition is the process of the drug particles reaching a specific area of the lungs.
Following deposition, the drug must adhere to the surface before being expelled through
exhalation. The surface of each lung section must be considered. In the conducting zones
of the airway, there is a mucus layer that may act as a barrier for drug particles.99,105 In
the respiratory zone, specifically the alveoli, there is lining fluid and surfactant.
Surfactant functions to reduce the surface tension and can facilitate the dissolution
process.99,106 Drug properties must also be considered to determine the level of
dissolution. Drug particles that are smaller in size overall have better dissolution.
Additionally, drugs that are more lipophilic have slower dissolution and remain in the
airway for longer periods of time. Since it takes longer for these types of molecules to
penetrate through the fluid layer and reach the lung tissue, these drugs may exhibit a
longer duration of action and less frequent dosing may be required.107
4.1.3 Clearance
Drug particles that are unable to reach the tissue layer of the lungs undergo clearance
through a variety of methods. These clearance methods include mucociliary clearance,
phagocytosis by macrophages, or systemic uptake.98,108 Mucociliary clearance is the
primary method of clearance in the conducting airways. This corresponds with the areas
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that have an increased mucus layer.99 Particles that are subject to mucociliary clearance
often are coughed out or swallowed.98 Particles that go deeper into the lungs to the
respiratory zone are less susceptible to this type of clearance. Instead, particles in the
deep lungs are predominately subject to phagocytosis by macrophages.108 However, drug
particles that are less than 200 nm are often unable to be recognized by macrophages.109
Few studies have been done specifically on macrophage phagocytosis of inhaled
nanoparticle chemotherapeutic agents.98 Particles deposited in the peripheral airways also
tend to be transported upwards and have an increased efficacy in the conducting
airway.99,108 Other particles located in the alveolar region are subject to lymph node
drainage.99 This could be advantageous to lung cancer that has metastasized to the lymph
nodes.98 Additionally, drugs that have been taken up into lymphatic circulation can
redistribute to other areas of the lungs which may be difficult to access otherwise.110
4.1.4 Absorption
The goal with inhalation therapy is for the drug to be absorbed before being cleared from
the lungs. The lipophilicity of the drug is particularly important to determine how well
the drug can be absorbed into the tissue. Drugs with a high lipophilicity and low
molecular weight absorb very rapidly. Nanoparticles offer an advantage as they can
penetrate the tissue more easily than other formulations.98 Lung absorption also depends
on the tumor's ability to absorb the drug. It has been proven that smaller nodules respond
better to inhaled treatment than larger nodules.111 Solid tumors also tend to have a denser
fibrous extracellular matrix consisting of collagen. The matrix can be difficult to
penetrate, especially for larger molecules.112 Administration of anti-fibrotic drugs, such
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as losartan, may provide an advantage by decreasing fibrosis and allowing for increased
drug uptake by the tissue.113
The respiratory tract has a humidity of approximately 99.5%. Drug products consisting of
salts (both new paclitaxel drugs considered) may absorb water from the lung
environment. Drugs containing salts could grow up to 50% of their size based on the salt
concentration.114 Further studies will have to be done to evaluate the extent of growth of
the paclitaxel formulations with copper and iron.
4.1.5 Retention
Drugs that can maintain effective concentrations in the lung are going to have an
increased efficacy verses drugs that are easily absorbed into the bloodstream and carried
away from the tumor site. Nanoparticles can maintain an increased concentration at the
site due to their sustained-release nature. Like albumin alone, nanoparticles tend to leak
from tumor vasculature due to the enhanced permeability and retention effect (EPR)
mentioned in Section 3.1.2.115 However, it is likely that EPR will not have much of an
effect for an inhaled drug. It is noted that the most important factor determining the tissue
retention of a drug is the pulmonary tissue partition coefficient, which relates to the
lipophilic properties of the drug.99
4.2 Safety and Administration
4.2.1 Safety and Contraindications
Nanoparticles are being studied more often for inhalation therapy due to the potential
benefits they offer. Based on studies that have been conducted, most inhaled
chemotherapies have been tolerated well in both animal and human studies. The two most
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common adverse effects are reported to be cough and bronchospasm, which are both
easily manageable.98
One consideration for aerosol administration is the health state of the patient's lungs.
There are some lung conditions that may obstruct the airway, and, in these cases,
inhalation may not be the best option due to the limited airway access. A study was
conducted to evaluate the success of aerosol drug delivery for obstructing conditions. It
was determined that drug deposition occurred until approximately 50% airway
obstruction.116 Other conditions may affect the patient's respiratory capacity. One study
evaluating inhaled insulin administration showed that patients with decreased lung
function were unable to sufficiently inhale an efficacious amount of drug product. These
patients had conditions such as chronic obstructive pulmonary disease (COPD),
emphysema, or bronchiectasis. Therefore, the conditions that are contraindicated for
inhaled chemotherapy include those mentioned, as well as severe uncontrolled
asthma.114,117 It should be noted that the addition of drugs such as bronchodilators and
corticosteroids enhanced deposition of drug particles regardless of which respiratory
disease was present.114
There have not been enough studies conducted to conclude if inhaled chemotherapy
presents a significant toxicity risk to healthy lung cells.98 However, one study concluded
that inhaled doxorubicin resulted in less cardiac toxicity than the same dose of
doxorubicin administered intravenously.118
4.2.2 Administration
There are many devices used to deliver aerosol particles to the lungs. Choosing an
appropriate device for inhaled chemotherapy use can be determined by considering the
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following factors: feasibility for patients, optimal delivery, and safety of device use. Most
inhaled drug delivery utilizes either inhalers or nebulizers. There are two types of
nebulizers: jet nebulizers and ultrasonic nebulizers. One of the main issues with
nebulizers is achieving adequate drug deposition. There are also two main types of
inhalers used for drug administration: dry powder inhalers and metered-dose inhalers.
Like nebulizers, these devices do not deliver adequate amounts of the drug product to the
lungs. Dry powder inhalers also show significant variation between different devices.110
Some testing on chemotherapeutic drugs has been conducted with nebulizers but there are
no studies found utilizing inhalers.114 There are also no current studies found exploring
the potential for using a vaporizer device for therapeutic drug use. The negative effects of
using these devices seem to be related to nicotine and flavorings that are added to the
vapor liquid. Further studies will need to be conducted to determine the device’s effects
on the lungs when these additives are not present. Section 4.3 of this paper will
demonstrate the capability for these devices to administer paclitaxel.
Many aerosol devices allow for escape of the drug product. These devices may not be
optimal for chemotherapeutic drugs due to safety reasons unless the drug is administered
utilizing special precautions for drug escape. The most optimal administration conditions
would include an area containing a HEPA filter fan unit, which captures up to 99.97% of
airborne particles.119 Use of chemotherapeutic agents in aerosol devices may also result
in mouth and throat irritation. Endotracheal administration may be optimal to reduce
these side effects in patients.
The potential setup for a device using endotracheal administration is shown in Figure 4.1.
This type of administration is not breath-actuated so the drug product must be pumped
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from the device. One option would be to pump the drug vapor using O2. Another option,
that has already been tested, would be to pump 5% CO2-enriched air. The use of CO2
increased deposition of inhaled paclitaxel liposomes in mice.120
The setup in Figure 4.1 consists of the following components surrounding a central
chamber: an electronic vaporizer, an O2/CO2 inlet valve, a vacuum value, and a delivery
valve. Each of these is connected to switches that should be electronically controlled.
First, the vaporizer valve opens and delivers the drug vapor into the central chamber. The
valve then closes, and the O2/CO2 valve and the delivery valve simultaneously open. The
influx of the gas pushes the vapor product out of the chamber and into the administration
tube which is connected to an endotracheal tube or other delivery device. Between these
cycles, all valves will close except for the vacuum valve, which will open and extract any
remaining drug vapor product from the chamber.
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Figure 4.1.

Model device for inhaled drug administration via endotracheal intubation.
Red arrows illustration the delivery of vapor product via O2/CO2. The yellow
arrows illustrate the “old vapor” that is to be removed following a
vaporization cycle.

4.3 Vaporization Trials
The ability of the drug to be carried over into the vapor state is necessary for proper
administration via an inhalation route. Two devices have been utilized to test this ability:
the KangerTech Top EVOD Vapor Pen and the Volcano Medic II by Storz and Bickel.
4.3.1 KangerTech Top EVOD Vapor Pen
The KangerTech Vapor Pen is a cylindrical device having a top-filling chamber with a
maximum capacity of 1.7 mL. The filling chamber includes a VOCC-T atomizer that is
responsible for heating the liquid and generating vapor. This specific atomizer contains a
cotton wick used to draw the liquid towards the heating element (coil). The atomizer
requires priming for 30 seconds before use and has a resistance of 1.5 ohms. Below the
filling chamber/atomizer is an EVOD battery. Many EVOD batteries operate at a
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maximum voltage that slowly decreases with battery usage. The KangerTech EVOD
maintains a voltage of 3.7 over the use period and plummets just before charge
indication. The battery capacity has a 650 mAh rating, indicating the power supply before
recharging. Considering Ohm’s law (I=V/R) and use of a low-resistance atomizer, more
current is drawn with each pull from the vapor pen, which discharges the battery more
quickly. The battery, when charged to full capacity, lasts between 4-6 hours with
consistent use. It is important to note that this vapor pen does not have temperature
control settings. Therefore, the operating temperature is variable depending on various
factors. Most vapor pens operate at temperatures between 160-220°C. The use of a lowresistance atomizer allows the coil to heat to higher temperatures, although exact
temperatures would need to be measured. This device is used in testing the vaporization
process because of its user-friendly nature and low cost (~20 USD). The battery
component contains a front-facing switch button that is used to turn the device on/off, as
well as control heating of the atomizer. To operate and heat the atomizer, the switch
button is held. Holding the button switches on the heating element and generates a
circumferential light around the button indicating use. The device will allow a maximum
hold of 10 seconds. For vapor to be expelled from the device, it requires suction while
simultaneously holding the switch button. The device comes with a mouthpiece that
allows users to directly inhale the vapor product.
4.3.2 KangerTech Vaporization Trials (Preliminary)
The purpose of the KangerTech trials is to confirm the basic vaporization capability of
paclitaxel. The KangerTech Vapor Pen is attached to the side connection of a vacuum
filtering flask using a rubber hose. The top of the vacuum flask is blocked with a stopper
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containing a glass tube. The glass tube is connected to a vacuum source via a rubber hose
(Figure 4.2). To pull vapor into the flask, the vacuum and switch button were activated
simultaneously. The vacuum uses a very low pressure to pull the vapor into the flask.
PAC and Cu5Fe5PAC were the drugs of focus for the vaporization trials. A series of
compositions were evaluated that include the drug components in various mole ratios.
The compositions are as follows: pure Paclitaxel; Cu-Paclitaxel; Cu5Paclitaxel; FePaclitaxel; Fe5Paclitaxel; and Cu5Fe5Paclitaxel. Table E.1 details the specific amount of
each component in the samples. Each formulation was dissolved in 15 mL of Ethanol
(EtOH) to create the drug solutions. Vapor production quality was classified using the
following parameters: low density vapor (barely visible to the eye); medium density
vapor (visible but not completely opaque); and high density vapor (completely opaque).

Figure 4.2.

Setup for KangerTech Vapor Pen trials.
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Trial one consisted of adding 0.5 mL of the ethanol-drug solution to the vapor pen. Using
a low viscosity liquid was problematic as vapor production proved to be very
inconsistent. The ethanol-drug solution alone produced only low and medium density
vapor. After each pull that resulted in medium density, the flask was washed with 0.5 mL
ethanol. This process was repeated until five medium density pulls were accomplished
(usually taking between 15-20 pulls total regardless of composition). As the contents of
the chamber diminished, the liquid risked burning, which occurred for a few of the
compositions. The vaporization process was repeated for these formulations. The vapor
product of each was then collected and analyzed via liquid chromatography-mass
spectrometry (LC-MS). Results indicated only traces of paclitaxel present and high
fragmentation of the paclitaxel molecule in each composition. This approach clarified the
need for a higher viscosity liquid for the trials.
A second trial, and the approach moving forward, included loading the vapor pen with a
mixture of propylene glycol/vegetable glycerin containing one part ethanol- drug (EtOHdrug) solution. Propylene glycol (PG) and vegetable glycerin (VG) are components that
are found either together or separately in electronic liquids. These components have a
much higher viscosity than ethanol and readily carry flavorings into the vapor phase in
vapor pens and other electronic smoking devices. These components are utilized in the
experiments due to both PG and VG being safe for consumption.121 The combination of
PG/VG and EtOH-drug in each mixture is added to total 0.5 mL of solution.
A ratio of 3:1 PG/VG was used. The PG/VG/EtOH-drug solution produces high density
vapor consistently until the liquid is nearly depleted from the chamber. The pulls lasted a
total of five seconds each to represent a normal deep inhale. A test trial showed that the
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number of pulls before a drop in vapor density is eight pulls. Therefore, eight pulls of
high density vapor was obtained for each formulation (Table 4.1). The vapor was allowed
to settle for seven minutes between each pull and washed with 0.5 mL ethanol between
every other pull. Following vaporization, the vapor product was allowed to settle for one
hour and was then collected and analyzed using LC-MS.
LC-MS results for pure paclitaxel in ethanol (non-vaporized) and PG/VG/EtOH- PAC
following vaporization are shown in Figure 4.3. The y-axis indicates the signal intensity.
As expected, a large peak of high intensity (x 100,000) is seen for PAC that has not been
through the vaporization process. This peak has a m/z ratio of 854. There is also a
significant peak for PAC + 2Na (m/z= 899). Following vaporization, we see a decrease in
intensity (to x 10,000) as would be expected. A large peak remains present for PAC alone
(m/z= 854) indicating successful vaporization without significant fragmentation. A large
peak is also seen for PAC + Na (m/z= 876). The peaks for PAC with Na and K are the
result of the ionization process and are common adducts seen with LC-MS testing.
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Figure 4.3.

LC-MS results for paclitaxel in ethanol.
A. Paclitaxel in ethanol before vaporization. B. Paclitaxel in ethanol vaporized in a
3:1 mixture of PG/VG using the KangerTech Vapor Pen.

Figure 4.4 contains the spectrum for the Cu5Fe5PAC drug following vaporization. Peaks
of significant intensity (x 10,000) are seen for PAC alone (m/z= 854) and PAC + Na
(m/z= 876). A peak is also seen for PAC + Cu at m/z= 917. A peak would have to be
present at m/z= 909 to indicate PAC + Fe, but this is not clearly shown. It is possible that
either fragmentation occurred with iron or that the vaporization process dislodges the iron
from the structure. Further testing will need to be done to evaluate iron behavior
following vaporization. Additional spectra for other drug formulations containing copper
and iron are included in Appendix E.
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Figure 4.4.

LC-MS results following vaporization of Cu5Fe5PAC in ethanol in a 3:1 mixture of
PG/VG using the KangerTech Vapor Pen.

4.3.3 Volcano Medic II
The Volcano Medic II is a medical-grade vaporizer manufactured and distributed by
Storz and Bickel. The device is so named because it features a conical shape like that of a
volcano in which the vapor product escapes from the top (more narrowed portion) of the
device. The device consists of a filling chamber, heating element, and air pump and
requires connection to a power supply for operation. The drug product is loaded in the
filling chamber and is absorbed by a drip pad. This is attached to the top of the Volcano
device. The concealed heating element consists of a spiral structure that uses convection
to reach the desired temperature. Then, through the process of conduction, the filling
chamber is heated. The main operations display on the front of the device allows for user
control of temperature between a range of 40-210ºC. Upon start-up, it takes
approximately 40 seconds to heat the vaporizer to 180ºC. The display contains a set
temperature reading which shows the desired temperature that was designated and an
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actual temperature reading that shows the current temperature of the device. Arrow
buttons allow the user to increase/decrease the set temperature.
There are a few ways to operate the device. One method includes using the air pump
function. The air pump pushes the vaporized product from the device at a rate of 12
l/min. The Volcano comes equipped with a tube and mouthpiece set that attaches to the
top of the vaporizer. The air function pushes the vapor product through the tube for
administration to the user. The other method of use includes creating a suction to pull the
vapor product through the tube for administration to the user. With either method, the
vapor cools rapidly while traveling through the tube.
4.3.4 Volcano Medic II Trials ⏤ Standard Ratio and Temperature
The first vaporization trials for the Volcano Medic including testing a 3:1:1 ratio of
propylene glycol (76.09 g/mol), vegetable glycerin (92.094 g/mol), and ethanol or
ethanol-drug to determine the number of pulses possible when set at a specific
temperature. The temperature of the vaporizer was set at 200ºC. Three combinations were
tested and compared to each other: (1) propylene glycol (PG), glycerin (VG), and ethanol
(EtOH); (2) propylene glycol (PG), glycerin (VG), and ethanol-PAC (EtOH-PAC); and
(3) propylene glycol (PG), glycerin (VG), and ethanol-Cu5Fe5PAC (EtOH-Cu5Fe5PAC).
The EtOH-PAC and EtOH- Cu5Fe5PAC were prepared as described in Section 2.2.1. For
each trial, 0.5 mL of the mixture was loaded into the vaporizer. The mouthpiece was
removed from the tubing to allow for connection of the device to a filtering flask. The air
function was utilized to push the vapor product into the flask. The top of the flask
contains a rubber stopper with a glass tube to allow for excess air to leave the flask. The
setup is shown in Figure 4.5.
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Figure 4.5.

Setup for Volcano Medic II trials.

The trials started by weighing an empty flask. The vaporization process was completed in
pulses lasting five seconds each. This length of time was selected to simulate a deep
inhale. After each pulse, the glass tube in the stopper was closed off to avoid escape of
the vapor. The flask was weighed one minute after each pulse to allow the vapor product
to settle before disconnection from the device. The trial was considered complete when
the weight of the flask no longer increased after a pulse, indicating no additional vapor
deposition.
Table 4.1 shows the change in flask weight with each pulse for each combination tested.
Tracking the cumulative weight increase with each pulse allows for visualization of the
efficiency of vapor deposition. Figure 4.6 graphically compares these changes for each
combination. The most pulses can be obtained for the PG, VG, ethanol combination, with
nine total pulses obtained with an increase in weight. The PG, VG, EtOH-PAC, and PG,
VG, EtOH- Cu5Fe5PAC trials both resulted in six total pulses. Based on total weight
increases, it is concluded that the heavier the mass of the solution added to the vaporizer,
the less vapor can be obtained. Compared to EtOH and EtOH-PAC, EtOH-Cu5Fe5PAC
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makes the solution heavier and likely results in the decrease in vapor deposition that is
seen (with only a maximum of 0.169 verses a maximum of 0.195 seen in EtOH-PAC).

Table 4.1.

Weight of flask after each vapor pulse of a 3:1:1 ratio of PG/VG/X. X= EtOH,
EtOH + PAC, or EtOH + Cu5Fe5PAC.
Green numbers indicate the change in weight from the starting weight of the flask.

Figure 4.6.

Graphical comparison of flask weight increase from starting weight per pulse of
vapor for a 3:1:1 ratio of PG/VG/X, with X being Ethanol, Ethanol + PAC, or
Ethanol + Cu5Fe5PAC.
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4.3.5 Volcano Medic II Trials ⏤ Variable Ratio and Temperature
Optimal temperatures for vaporizing are variable depending on the material being
vaporized. Little information is available regarding the optimal temperatures for each
PG/VG mixture. Most information found regarding temperature control considers factors
such as vapor flavor and smoothness. These variables are negligible for drug vaporization
since no flavor additives are present. Standard recommendations for vaporization
temperature are as follows: light vapor at 325- 350ºF (163-177ºC), optimal temperature
zone at 350-375ºF (177-191ºC), thick vapor at 375-400ºF (191-205ºC), and danger zone
for combustion or burning at 400ºF (205ºC) and up.122 These recommendations are not
specific to any certain material, so it is necessary to conduct testing to see which
temperature is best for a given mixture. Additionally, a factor that is not considered is
amount of vapor deposition with each pull/pulse of the vapor product. This would give a
quantitative factor to consider for optimal temperature verses the qualitative factors that
are typically discussed.
Various ratios (3:1, 1:3, and 1:1) of PG/VG with EtOH-PAC were tested against the
following temperatures: 160ºC, 170ºC, 180ºC, 190ºC, 200ºC, and 210ºC. The experiment
set up is the same as in Figure 4.5. 0.5 mL of the solution was added to the Volcano
Medic device. The vaporization process was done in pulses lasting five seconds each.
After each pulse, the vapor product settled for one minute before weighing. The final
weight of the flask was compared to the starting weight of the empty flask to determine
amount of vapor deposition. Corresponding graphs containing this information are
included in the text for easy comparison. Tables that include this information are found in
Appendix E. The samples yielding the most deposition by weight were analyzed via LC-
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MS to determine if the vapor easily carried the paclitaxel molecule. The LC-MS spectra
of each vapor product was compared in intensity to pure paclitaxel in ethanol.
The first mixture is in a 3:1 ratio of PG/VG. This is the standard PG/VG combination that
is most often seen in vaping liquids. A test trial of this combination yielded a total of
eight high density pulses with the KangerTech Top EVOD vapor pen.
Changes in the flask weight between pulses indicate the amount of vapor deposition per
pulse. Figure 4.7 compares these values across temperatures ranging from 160ºC-210ºC
for the 3:1 PG/VG mixture. Changes in flask weight (deposition) from the starting weight
is ranked as follows: <0.050=low; 0.050 to 0.150= moderate; and 0.150 to 0.300= high.
The sample at 160ºC had low deposition (0.036 g) across two pulses obtained where
deposition occurred. It is predicted that other samples below this temperature will also
have low vapor deposition. Samples at 180ºC, 190ºC, and 210ºC had overall moderate
deposition (from 0.099 to 0.147 g) across four pulses. After four pulses, deposition
declined for each temperature. Therefore, these temperatures may be utilized but are not
the most efficient for the given mixture. The samples at 200ºC and 170ºC had high
deposition. The sample at 200ºC had the most rapid deposition per pulse of all samples.
However, deposition reached its highest point at five pulses (0.208 g). The sample at
170ºC was able to deposit more vapor than all other samples (0.277 g), and steadily
increased in vapor deposition across eight pulses. It is concluded that for the 3:1 ratio, a
temperature of 170ºC seems to be the most successful at vapor generation.
A 1:3 ratio of PG/VG with EtOH-PAC is considered. This ratio is the opposite of the
commonly used mixture. An advantage of using this combination includes generation of
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a thicker vapor.123 Whether or not that means an increase in vapor/paclitaxel deposition is
unknown and is one reason for testing the combination.

Figure 4.7.

Graphical comparison of flask weight increase from starting weight per each pulse
of vapor for a 3:1 ratio of PG/VG with EtOH-PAC across various temperatures.

Figure 4.8 shows the change in flask weight across pulses for the 1:3 ratio of PG/VG. The
sample at 190ºC had low overall vapor deposition (0.019 g) across only four pulses
obtained. Those at 160ºC and 180ºC had moderate vapor deposition. The sample at 160ºC
had more deposition (0.092 g) than the sample at 180ºC (0.083 g), even though only five
pulses were obtained verses nine. The samples at 170ºC, 200ºC, and 210ºC all had high
deposition. The samples at 170ºC and 210ºC yielded similar results, with the 170ºC
sample having overall higher deposition (0.207 g) across nine pulses verses the 210ºC
sample having slightly less deposition (0.184 g) across ten pulses. The best temperature
for vapor deposition of the 1:3 PG/VG mixture seems to be 200ºC (deposition= 0.260 g).
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However, to achieve maximum deposition at this temperature, thirteen pulses must be
done.

Figure 4.8.

Graphical comparison of flask weight increase from starting weight per each pulse
of vapor for a 1:3 ratio of PG/VG with EtOH-PAC across various temperatures.

A 1:1 ratio of PG/VG with EtOH-PAC is considered and tested. This combination is a
middle-ground between the two mixtures previously considered. Figure 4.9 shows the
change in flask weight across pulses. There were no samples with low deposition like
with the other two mixtures. The sample at 160ºC is the only sample with moderate
deposition although it nearly reaches the range considered high deposition (0.145 g). The
170ºC sample performed slightly better than the 160ºC, with a weight increase of 0.185 g
verses 0.145 g. Seven pulses were obtained at both temperatures. The samples at 190ºC
and 200ºC had overall very similar vapor deposition. The 200ºC sample deposited vapor
(0.253 g) over ten pulses whereas the sample at 190ºC deposited nearly the same amount
(0.257 g) over twelve pulses. The best temperature for vapor deposition of the 1:1 ratio of
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PG/VG seems to be 210ºC. The sample deposited the most vapor (0.270 g) at this
temperature and only eight pulses were necessary to obtain this high level of deposition.

Figure 4.9.

Graphical comparison of flask weight increase from starting weight per each pulse
of vapor for a 1:1 ratio of PG/VG with EtOH-PAC across various temperatures.

The temperatures with the best vapor deposition based on changed in flask weight from
all three mixtures are 3:1 PG/VG at 170ºC, 1:3 PG/VG at 200ºC, and 1:1 PG/VG at
210ºC. These are compared in Figure 4.10. The amount of vapor deposition is highly
variable across each PG/VG mixture and temperature. The best overall deposition is
obtained with a 3:1 PG/VG mixture at 170ºC. The 1:1 PG/VG mixture at 210ºC yielded
very similar results. Both samples achieved deposition with flask weight being within
0.007 g of each other across eight pulses. The 1:3 PG/VG at 200ºC achieves a similar
overall deposition but this process takes much more time, shown by the thirteen pulses
obtained. It must be noted that the ratio containing more VG is described as creating
thicker exhaled vapor. This must be considered for drug delivery due to risk of losing
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drug product in exhaled vapor. However, this would need to be studied further to confirm
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Figure 4.10. Graphical comparison of the best vaporization combinations from PG/VG
mixtures.

The total weight of the solvent components was calculated per mixture and compared to
flask weight following vaporization to determine how efficient each mixture was at its
most optimal temperature. This data is found in Table 4.2. It must be noted that the
efficiency is calculated based on the weight of all components added together and does
not account specifically for efficiency of paclitaxel alone. LC-MS data later discussed
gives a better indication of paclitaxel transfer in vapor for each mixture.
The efficiency results follow the same trend as vapor deposition. The most efficient
mixture based on total weight obtained from starting weight of solution is the 3:1 PG/VG
mixture at 170ºC, with an efficiency of 53.6%. The total weight of components in this
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mixture was the least of all that were tested but yielded the most vapor product. The least
efficient mixture was the 1:3 PG/VG mixture at 200ºC, with an efficiency of 46.3%. The
starting weight of this mixture was the heaviest, but the vaporization process yielded the
least amount of vapor product. This result also reinforced the first vaporization trial
showing that mixtures with less weight produce more vapor yield.

Table 4.2.

Comparison of efficiency of vaporization between highest yielding samples of 3:1
PG/VG, 1:3 PG/VG, and 1:1 PG/VG with EtOH-PAC.

Mass spectrometry data was obtained for each mixture at the temperature that generated
the highest increase in flask weight (vapor deposition). LC-MS data acts to determine if
the amount of vapor deposition has a positive relationship with the amount of paclitaxel
in the vapor product. The mixtures and temperatures are as follows: 3:1 PG/VG with
EtOH-PAC at 170ºC; 1:3 PG/VG with EtOH-PAC at 200ºC; and 1:1 PG/VG with EtOHPAC at 210ºC. The vapor product for the 3:1 PG/VG mixture at 200ºC was also analyzed
since this temperature and mixture was used in the initial Volcano trials.
The LC-MS result of pure paclitaxel in ethanol is found in Figure 4.11. This spectrum
shows the drug before vaporization and is used to measure the intensity of samples that
went through the vaporization process. Paclitaxel is seen at 854 with a large intensity of
1.4 x 1,000,000.
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Figure 4.11. LC-MS results for paclitaxel in ethanol.

The spectra of the vapor products for the 3:1 mixture of PG/VG with EtOH-PAC at
170ºC and 200ºC are shown in Figure 4.12. Paclitaxel is seen in both at m/z= 854.
Paclitaxel + Na is also detected in both at a m/z of 876. The intensity of paclitaxel in the
sample at 200ºC is much greater than that in the 170ºC sample (0.92 x 100,000 vs 2.05 x
10,000) and is shown by the clearly defined peaks. These results indicate that a
temperature of 170ºC may not be high enough to effectively carry large molecules in
sufficient quantities, as shown by the amount of fragmentation present. Therefore, a
temperature of 200ºC is recommended for the standard 3:1 PG/VG combination.
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Figure 4.12. LC-MS results for the vapor product of a 3:1 mixture of PG/VG with EtOH-PAC
vaporized using the Volcano Medic II. A. Sample vaporized at 170ºC. B. Sample
vaporized at 200ºC.

The 1:3 PG/VG with EtOH-PAC sample at 200ºC was analyzed. This mixture and
temperature yielded the highest intensity of paclitaxel in vapor of all samples, with the
intensity being 1.95 x 100,000. The spectrum is shown in Figure 4.13. This sample can be
directly compared to the 3:1 PG/VG vapor sample at the same temperature. The
paclitaxel intensity in the 1:3 PG/VG mixture after vaporization is over double that of the
3:1 PG/VG mixture. This indicates that the observed thicker vapor results in an increased
accumulation of paclitaxel.
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Figure 4.13. LC-MS results for the vapor product of a 1:3 mixture of PG/VG with EtOH-PAC
vaporized at 200ºC using the Volcano Medic II.

LC-MS results for the 1:1 PG/VG with EtOH-PAC mixture is shown in Figure 4.14.
Larger peaks are seen for both paclitaxel (m/z= 854) and paclitaxel + Na (m/z= 876), but
the intensity of these are relatively low (2.05 x 10,000). In this case, the lower yield
cannot be contributed to a low temperature since the temperature tested is at 210ºC. It is
predicted that the lower yield may be due to this temperature being too high for the given
mixture causing high fragmentation, as shown.

76

Figure 4.14. LC-MS results for the vapor product of a 1:1 mixture of PG/VG with EtOH-PAC
vaporized at 210ºC using the Volcano Medic II.

Integration of efficiency data and LC-MS results for the high deposition samples in Table
4.2 indicate that high vaporization efficiency does not equate to high paclitaxel intensity
in vapor. This is shown with the sample with more VG (3:1 PG/VG) having the highest
paclitaxel concentration in vapor but the lowest vaporization efficiency. The increased
paclitaxel concentration in this sample is likely due to the increased viscosity of glycerol.
For samples with more propylene glycol than glycerol, the temperature must be higher to
get a similar paclitaxel vapor yield, as seen with the 3:1 PG/VG samples at 200ºC vs
170ºC. Temperatures for any given mixture should not be set to above 200ºC so that
fragmentation of the large paclitaxel molecule is avoided. Temperatures below 200ºC for
any given mixture seem to either have lower vapor concentration of paclitaxel or overall
low vapor deposition. Therefore, 200ºC seems to be a reasonable temperature for any
combination.
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CONCLUSION

Paclitaxel (Taxol) earned a reputation for being history’s best-selling cancer medication.
To overcome the challenges of poor solubility, new drug delivery systems have been
explored which include methods such as utilization of lipid vehicles or reduced drug
particle size. Several novel paclitaxel-containing drugs have been synthesized and tested
against the National Cancer Institute’s (NCI) in vitro sixty cell line panel. The two drug
complexes of interest include (CUPAC)5GLU12DALB and Cu5Fe5PAC. The added
excipients in Cu5Fe5PAC and (CUPAC)5GLU12DALB act to improve therapeutic
efficacy of paclitaxel by impacting factors such as water solubility, serum lifetime,
breakdown, etc. The two drugs discussed offer these advantages over pure paclitaxel and
Cremophor-EL-containing paclitaxel (Taxol). The drugs also present a novel mechanism
of action which includes disguising the drug by nutrient-complexation.
The purpose of analytical testing in this study was not to define the structures of the drug
molecules, but to understand the basic behavior of the various drug components and how
they interact with each other to form the crystalline complexes. MALDI-TOF-MS results
display clear peaks demonstrating paclitaxel complexed with both copper and iron. This
testing also shows a strong interaction between DALB and copper and no interaction
between paclitaxel and albumin, indicating that paclitaxel is bound to DALB through
copper complexation. 1H-NMR spectra reinforce the findings from MALDI-TOF testing.
FT-IR spectral analysis allowed for definition of peaks contributed to bonds of pure
paclitaxel. Using this information, changes to the spectrum are able to be deduced to the
interactions of the other drug components, like iron or DALB.
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NCI sixty cell line data tested three parameters: GI50, LC50 and TGI. Two sample z-test
results compared the values of Cu5Fe5PAC and pure PAC, as well as CPGD and pure
PAC, to determine if the values were statistically different. Using a confidence interval of
95%, results showed that GI50 values, LC50 values, and TGI values for Cu5Fe5PAC and
PAC were significantly different, with PAC having higher activity for each parameter.
GI50 and LC50 values for CPGD and PAC also proved to be significantly different, with
PAC having higher activity. Results also showed that CPGD may be more effective than
PAC at killing cancer cells and is comparable to PAC in terms of total growth inhibition
(TGI). Cu5Fe5PAC values are not as successful as PAC but still present a high amount of
anticancer activity. It is important to note that these tests are carried out in vitro.
Evaluation of each drug in vivo would give a better idea of its full efficacy and the tumor
targeting capabilities of the components added.
The ability of paclitaxel-containing drugs to be vaporized was a major focus of this study.
Lung cancer is the deadliest cancer type, with an average survival rate of 21.7% based on
data from 2011-2017.124 Inhaled chemotherapy has not been extensively studied but
offers a solution for patients with lung cancers who experience toxicity because of
traditional treatment. Studies will need to be conducted in the future to evaluate all safety
aspects of drug administration.
Conclusions regarding optimal particles for inhalation are gathered based on known
information of lung anatomy and inhaled particle behavior. The drug particles must be
able to reach the target area of the lungs and avoid being exhaled, adhere to the lung
surface, avoid excessive clearance, absorb into the lung tissue, and retain itself in the
tumor environment.
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The main characteristics of the particles considered are size (aerodynamic diameter) and
lipophilicity. Both drugs synthesized (Cu5Fe5PAC and CPGD) are nanoparticles and are
approximately 100 nm in diameter. Particles between 500 nm-1 μm have the tendency to
be exhaled after reaching the airway. Since the drug particles are smaller than this, an
increase in deposition is likely to occur. Holding the breath following inhalation may also
increase deposition of the ultrafine particles. This size is optimal to avoid mucociliary
clearance after depositing on the lung surface. The small particle size also increases the
ability of the drug to be absorbed into the tissue.
The KangerTech Top EVOD Vapor Pen offers a small, portable solution to vaporization.
The variability of the temperature during a vapor pull likely results in mixed outcomes in
terms of vapor production. Although the device is reasonably priced and very userfriendly, it is not the most optimal for administration of chemotherapeutic agents. Trials
conducted using this device are still useful for suggesting that even the most basic
vaporizing devices have the ability to carry over large molecules into the vapor.
The Volcano Medic II by Storz and Bickel offers an excellent solution for
chemotherapeutic drug vaporization. The device is much more efficient and offers a wide
range of control. With the use of a propylene glycol/vegetable glycerin mixture, a large
amount of drug can carry over into the vapor. The trials suggest that the higher the
viscosity of a solution, the more drug yield there is in the vapor. PG/VG is currently used
due to being safe for consumption and readily available. Each PG/VG mixture seems to
have variable vaporization results at the temperatures that were tested. The best
temperatures and mixtures discussed may only present high-yielding results for paclitaxel
vaporization, as this was the only drug evaluated at this time. Vaporization of other drugs
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will need to be tested against these temperatures and mixtures to see if the drug itself has
any effect on its yield with the PG/VG mixture.
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APPENDIX A ⏤Cell Line Information

Cell Line

Cancer
Type
Leukemia

Doubling
Time (hr)
26.7

HL-60(TB)

Leukemia

28.6

K-562

Leukemia

19.6

MOLT-4

Leukemia

27.9

RPMI-8226

Leukemia

33.5

SR

Leukemia

28.7

A549/ATC
C

NSCLC

22.9

EKVX

NSCLC

43.6

HOP-62

NSCLC

39

HOP-92

NSCLC

79.5

NCI-H226

NSCLC

61

NCI-H23

NSCLC

33.4

NCIH322M

NSCLC

35.3

NCI-H460

NSCLC

17.8

CCRFCEM

Origin (%
genome)
North
European
(69.4%)
N/A
North
European
(43.44%)
North
European
(68.08%)
African
(73.94%)
North
European
(62.78%)
North
European
(66.12%)
North
European
(67.1%)
North
European
(63.51%)
North
European
(74.13%)
North
European
(65.62%)
African
(67.86%)
North
European
(72.75%)
North
European
(65.65%)

Source Description (using
Cellosaurus)
4 year old female with acute
lymphoblastic leukemia
36 year old female with acute
myeloid leukemia
53 year old female with blast
phase chronic myelogenous
leukemia
19 year old male with acute
lymphoblastic leukemia
61 year old male with multiple
myeloma
11 year old male with
anaplastic large cell lymphoma
58 year old male with lung
adenocarcinoma
Male of unspecified age with
lung adenocarcinoma
60 year old female with lung
adenocarcinoma
62 year old male with lung nonsmall cell carcinoma
Male of unspecified age with
pleural epithelioid
mesothelioma
51 year old male with lung
adenocarcinoma
52 year old make with
minimally invasive lung
adenocarcinoma
Male of unspecified age with
lung large cell carcinoma
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NCI-H522

NSCLC

38.2

COLO 205

Colon

23.8

HCC-2998

Colon

31.5

HCT-116

Colon

17.4

HCT-15

Colon

20.6

HT29

Colon

19.5

KM12

Colon

23.7

SW-620

Colon

20.4

SF-268

CNS

33.1

SF-295

CNS

29.5

SF-539

CNS

35.4

SNB-19

CNS

34.6

SNB-75

CNS

62.8

U251

CNS

23.8

Melanoma

20.5

LOX IMVI

North
European
(69.74%)
North
European
(61.39%)
South
European
(53.15%)
North
European
(64.85%)
North
European
(49.17%)
South
European
(63.24%)
North
European
(63.68%)
North
European
(50.01%)
North
European
(65.25%)
North
European
(72.83%)
South
European
(60.44%)
North
European
(78.25%)
North
European
(57.46%)
North
European
(79.45%)
North
European
(67.19%)

58 year old male with lung
adenocarcinoma
70 year old male with colon
adenocarcinoma
Person of unidentified age and
sex with colon adenocarcinoma
48 year old male with colon
carcinoma
Male of unspecified age with
colon adenocarcinoma
44 year old female with colon
adenocarcinoma
Person of unidentified age and
sex with colon carcinoma
51 year old male with colon
adenocarcinoma
24 year old female with
astrocytoma
67 year old female with
glioblastoma
34 year old female with
gliosarcoma
75 year old male with
astrocytoma
75 year old female with
glioblastoma
75 year old male with
astrocytoma
58 year old male with
amelanotic melanoma
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MALME3M

Melanoma

46.2

M14

Melanoma

26.3

MDA-MB435
SK-MEL-2

Melanoma

25.8

Melanoma

45.5

SK-MEL28

Melanoma

35.1

SK-MEL-5

Melanoma

25.2

UACC-257

Melanoma

38.5

UACC-62

Melanoma

31.3

IGROV1

Ovarian

31

OVCAR-3

Ovarian

34.7

OVCAR-4

Ovarian

41.4

OVCAR-5

Ovarian

48.8

OVCAR-8

Ovarian

26.1

NCI-ADRRES

Ovarian

34

SK-OV-3

Ovarian

48.7

North
European
(66.47%)
North
European
(67.89%)
N/A
South
European
(58.89%)
South
European
(64.91%)
North
European
(60.03%)
North
European
(65.94%)
North
European
(67.39%)
South
European
(47.29%)
North
European
(60.92%)
North
European
(53.46%)
North
European
(67.06%)
North
European
(60.74%)
N/A
North
European
(59.05%)

43 year old male with
melanoma
33 year old male with
amelanotic melanoma
33 year old male with
amelanotic melanoma
60 year old male with
melanoma
51 year old male with
cutaneous melanoma
24 year old female with
cutaneous melanoma
Person of unidentified age and
sex with melanoma
Person of unidentified age and
sex with melanoma
47 year old female with ovarian
endometrioid adenocarcinoma
60 year old female with high
grade ovarian serous
adenocarcinoma
42 year old female with high
grade ovarian serous
adenocarcinoma
67 year old female with high
grade ovarian serous
adenocarcinoma
64 year old female with high
grade ovarian serous
adenocarcinoma
64 year old female with high
grade ovarian serous
adenocarcinoma
64 year old female with ovarian
serious cystadenocarcinoma

786-0

Renal

22.4

A498

Renal

66.8

ACHN

Renal

27.5

CAKI-1

Renal

39

RXF 393

Renal

62.9

SN12C

Renal

29.5

TK-10

Renal

51.3

UO-31

Renal

41.7

PC-3

Prostate

27.1

DU-145

Prostate

32.3

MCF7

Breast

25.4

MDA-MB231/ATCC

Breast

41.9

HS 578T

Breast

53.8

BT-549

Breast

53.9

T-47D

Breast

45.5

North
European
(65.75%)
North
European
(63.47%)
North
European
(70.53%)
South
European
(58.26%)
North
European
(57.95%)
North
European
(64.97%)
South
European
(73.4%)
North
European
(65.67%)
North
European
(65.73%)
North
European
(63.74%)
North
European
(56.91%)
South
European
(60.03%)
North
European
(63.73%)
South
European
(62.87%)
South
European
(62.69%)
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58 year old male with renal cell
carcinoma
52 year old male with renal cell
carcinoma
22 year old male with papillary
renal cell carcinoma
49 year old male with clear cell
renal cell carcinoma
54 year old male with renal cell
carcinoma
Male of unspecified age with
renal cell carcinoma
43 year old male with clear cell
renal cell carcinoma
Female of unspecified age with
renal cell carcinoma
62 year old male with prostate
carcinoma
69 year old male with prostate
carcinoma
69 year old female with
invasive breast carcinoma of no
special type
51 year old female with breast
adenocarcinoma
74 year old female with
invasive breast carcinoma of no
special type
72 year old female with
invasive breast carcinoma of no
special type
54 year old female with
invasive breast carcinoma of no
special type
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MDA-MB468

Breast

62

African
(80.3%)

51 year old female with breast
adenocarcinoma
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APPENDIX B ⏤ Cu5Fe5PAC Data
Table B.1.

1

Assignment
H1
H2, H6
H3, H5
H4
H7
H8-H10
H11
H12
H13
H14
H15
H16
H17-H19
H20
H21-H23
H24
H25
H26
H27, H31
H28, H30
H29
H32, H36
H33, H35
H34
H37
H38
H39-H41
H42-H44
H45-H47
OH1
OH2
OH3
NH1

H-NMR assignments for paclitaxel versus Cu5PAC in CDCl3.

PAC Shift (observed)
5.6907
8.1814
7.5555
7.6744
3.8418
2.4318
4.3201
4.2092
4.9912
2.5477
1.8546
4.4413
1.6807
6.3022
2.2301
6.2625
4.8357
5.8081
7.7790
7.4367
7.4828
7.4664
7.4519
7.3969
2.3995
2.3045
1.8215
1.2694
1.1658
2.4825
3.6591
1.9728
7.0672

Cu5PAC Shift (observed)
5.3585
8.1849
7.5544
7.6753
3.8369
2.4322
4.321
4.2105
4.9923
2.5484
1.8714
4.4420
1.6673
6.3033
2.2532
6.2638
4.8365
5.7507
7.7833
7.4374
7.4856
7.4695
7.4535
7.3983
2.3809
2.3057
1.8218
1.2706
1.1667
2.48
3.6612
1.9872
7.0682

Figure B.1.

Dose response curves for Cu5Fe5PAC (provided by the National Cancer Institute).
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Figure B.2.

In-vitro test results for Cu5Fe5PAC. (provided by the National Cancer Institute).

Figure B.3.

Mean graphs for Cu5Fe5PAC (provided by the National Cancer Institute).
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Figure B.4.

Dose response curves of all cell lines for Cu5Fe5PAC (provided by the National Cancer Institute).
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Figure C.1.

Dose response curves for (CUPAC)5GLU12DALB (provided by the National Cancer Institute).
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APPENDIX C ⏤ (CUPAC)5GLU12DALB Data
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Figure C.2.

In-vitro test results for (CUPAC)5GLU12DALB. (provided by the National Cancer
Institute).

Figure C.3.

Mean graphs for (CUPAC)5GLU12DALB (provided by the National Cancer Institute).
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Figure C.4.

Dose response curves of all cell lines for (CUPAC)5GLU12DALB (provided by the National Cancer
Institute).
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APPENDIX D ⏤ Pure Paclitaxel Data

Table D.1. In-vitro GI50 test results for paclitaxel.
nsc

endpoint expId

descriptor for
display

cell panel

cell line

test
result

125973 GI50

AVGDATA paclitaxel
(Taxol)

Small Cell
Lung

DMS114

-8.537

125973 GI50

AVGDATA paclitaxel
(Taxol)

Small Cell
Lung

DMS273

-8.505

125973 GI50

AVGDATA paclitaxel
(Taxol)

Leukemia

CCRF-CEM -8.539

125973 GI50

AVGDATA paclitaxel
(Taxol)

Leukemia

HL-60(TB)

-8.415

125973 GI50

AVGDATA paclitaxel
(Taxol)

Leukemia

K-562

-8.422

125973 GI50

AVGDATA paclitaxel
(Taxol)

Leukemia

MOLT-4

-8.31

125973 GI50

AVGDATA paclitaxel
(Taxol)

Leukemia

RPMI-8226 -8.568

125973 GI50

AVGDATA paclitaxel
(Taxol)

Leukemia

SR

125973 GI50

AVGDATA paclitaxel
(Taxol)

NonA549/ATCC -8.386
SmallCellLung

125973 GI50

AVGDATA paclitaxel
(Taxol)

NonEKVX
SmallCellLung

-7.174

125973 GI50

AVGDATA paclitaxel
(Taxol)

NonHOP-18
SmallCellLung

-6.803

125973 GI50

AVGDATA paclitaxel
(Taxol)

NonHOP-62
SmallCellLung

-7.914

125973 GI50

AVGDATA paclitaxel
(Taxol)

NonHOP-92
SmallCellLung

-7.067

125973 GI50

AVGDATA paclitaxel
(Taxol)

NonNCI-H226
SmallCellLung

-7.198

125973 GI50

AVGDATA paclitaxel
(Taxol)

NonNCI-H23
SmallCellLung

-8.412

125973 GI50

AVGDATA paclitaxel
(Taxol)

NonNCI-H322M -7.983
SmallCellLung

125973 GI50

AVGDATA paclitaxel
(Taxol)

NonNCI-H460
SmallCellLung

-8.404

-8.535

(cont. on next page)
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Table D.1 (cont.)
125973 GI50

AVGDATA paclitaxel
(Taxol)

NonNCI-H522
SmallCellLung

-8.28

125973 GI50

AVGDATA paclitaxel
(Taxol)

NonLXFL529
SmallCellLung

125973 GI50

AVGDATA paclitaxel
(Taxol)

Colon

COLO205

-8.517

125973 GI50

AVGDATA paclitaxel
(Taxol)

Colon

DLD-1

-7.259

125973 GI50

AVGDATA paclitaxel
(Taxol)

Colon

HCC-2998

-8.468

125973 GI50

AVGDATA paclitaxel
(Taxol)

Colon

HCT-116

-8.575

125973 GI50

AVGDATA paclitaxel
(Taxol)

Colon

HCT-15

-6.787

125973 GI50

AVGDATA paclitaxel
(Taxol)

Colon

HT29

-8.574

125973 GI50

AVGDATA paclitaxel
(Taxol)

Colon

KM12

-8.439

125973 GI50

AVGDATA paclitaxel
(Taxol)

Colon

KM20L2

-8.551

125973 GI50

AVGDATA paclitaxel
(Taxol)

Colon

SW-620

-8.492

125973 GI50

AVGDATA paclitaxel
(Taxol)

CNS

SF-268

-8.22

125973 GI50

AVGDATA paclitaxel
(Taxol)

CNS

SF-295

-7.924

125973 GI50

AVGDATA paclitaxel
(Taxol)

CNS

SF-539

-8.453

125973 GI50

AVGDATA paclitaxel
(Taxol)

CNS

SNB-19

-8.016

125973 GI50

AVGDATA paclitaxel
(Taxol)

CNS

SNB-75

-8.475

125973 GI50

AVGDATA paclitaxel
(Taxol)

CNS

SNB-78

-8.008

125973 GI50

AVGDATA paclitaxel
(Taxol)

CNS

U251

-8.439

125973 GI50

AVGDATA paclitaxel
(Taxol)

CNS

XF498

-8.458

125973 GI50

AVGDATA paclitaxel
(Taxol)

Melanoma

LOXIMVI

-8.453

(cont. on next page)
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Table D.1 (cont.)
125973 GI50

AVGDATA paclitaxel
(Taxol)

Melanoma

MALME-3M -7.44

125973 GI50

AVGDATA paclitaxel
(Taxol)

Melanoma

M14

-8.245

125973 GI50

AVGDATA paclitaxel
(Taxol)

Melanoma

MDA-MB435

-8.41

125973 GI50

AVGDATA paclitaxel
(Taxol)

Melanoma

M19-MEL

-8.511

125973 GI50

AVGDATA paclitaxel
(Taxol)

Melanoma

SK-MEL-2

-7.642

125973 GI50

AVGDATA paclitaxel
(Taxol)

Melanoma

SK-MEL-28 -7.328

125973 GI50

AVGDATA paclitaxel
(Taxol)

Melanoma

SK-MEL-5

-8.429

125973 GI50

AVGDATA paclitaxel
(Taxol)

Melanoma

UACC-257

-7.66

125973 GI50

AVGDATA paclitaxel
(Taxol)

Melanoma

UACC-62

-8.382

125973 GI50

AVGDATA paclitaxel
(Taxol)

Ovarian

IGROV1

-8.173

125973 GI50

AVGDATA paclitaxel
(Taxol)

Ovarian

OVCAR-3

-8.367

125973 GI50

AVGDATA paclitaxel
(Taxol)

Ovarian

OVCAR-4

-6.332

125973 GI50

AVGDATA paclitaxel
(Taxol)

Ovarian

OVCAR-5

-7.405

125973 GI50

AVGDATA paclitaxel
(Taxol)

Ovarian

OVCAR-8

-8.3

125973 GI50

AVGDATA paclitaxel
(Taxol)

Ovarian

NCI/ADRRES

-5.545

125973 GI50

AVGDATA paclitaxel
(Taxol)

Ovarian

SK-OV-3

-8.095

125973 GI50

AVGDATA paclitaxel
(Taxol)

Renal

786-0

-7.878

125973 GI50

AVGDATA paclitaxel
(Taxol)

Renal

A498

-7.229

125973 GI50

AVGDATA paclitaxel
(Taxol)

Renal

ACHN

-6.343

125973 GI50

AVGDATA paclitaxel
(Taxol)

Renal

CAKI-1

-6.661

(cont. on next page)
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Table D.1 (cont.)
125973 GI50

AVGDATA paclitaxel
(Taxol)

Renal

RXF393

-8.191

125973 GI50

AVGDATA paclitaxel
(Taxol)

Renal

RXF-631

125973 GI50

AVGDATA paclitaxel
(Taxol)

Renal

SN12C

-8.344

125973 GI50

AVGDATA paclitaxel
(Taxol)

Renal

TK-10

-7.543

125973 GI50

AVGDATA paclitaxel
(Taxol)

Renal

UO-31

-5.994

125973 GI50

AVGDATA paclitaxel
(Taxol)

Prostate

PC-3

-8.387

125973 GI50

AVGDATA paclitaxel
(Taxol)

Prostate

DU-145

-8.365

125973 GI50

AVGDATA paclitaxel
(Taxol)

Breast

MCF 7.00

-8.552

125973 GI50

AVGDATA paclitaxel
(Taxol)

Breast

MDA-MB231/ATCC

-8.002

125973 GI50

AVGDATA paclitaxel
(Taxol)

Breast

HS578T

-8.525

125973 GI50

AVGDATA paclitaxel
(Taxol)

Breast

MDA-N

-8.602

125973 GI50

AVGDATA paclitaxel
(Taxol)

Breast

BT-549

-8.363

125973 GI50

AVGDATA paclitaxel
(Taxol)

Breast

T-47D

-7.491

125973 GI50

AVGDATA paclitaxel
(Taxol)

Breast

MDA-MB468

-8.412
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Table D.2. In-vitro LC50 test results for paclitaxel.
nsc

endpoint expId

descriptor for
display

cell panel

cell line

test
result

125973 LC50

AVGDATA paclitaxel
(Taxol)

Small Cell
Lung

DMS114

-4.648

125973 LC50

AVGDATA paclitaxel
(Taxol)

Small Cell
Lung

DMS273

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Leukemia

CCRF-CEM -4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Leukemia

HL-60(TB)

-4.628

125973 LC50

AVGDATA paclitaxel
(Taxol)

Leukemia

K-562

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Leukemia

MOLT-4

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Leukemia

RPMI-8226 -4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Leukemia

SR

125973 LC50

AVGDATA paclitaxel
(Taxol)

NonA549/ATCC -4.602
SmallCellLung

125973 LC50

AVGDATA paclitaxel
(Taxol)

NonEKVX
SmallCellLung

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

NonHOP-18
SmallCellLung

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

NonHOP-62
SmallCellLung

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

NonHOP-92
SmallCellLung

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

NonNCI-H226
SmallCellLung

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

NonNCI-H23
SmallCellLung

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

NonNCI-H322M -4.602
SmallCellLung

125973 LC50

AVGDATA paclitaxel
(Taxol)

NonNCI-H460
SmallCellLung

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

NonNCI-H522
SmallCellLung

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

NonLXFL529
SmallCellLung

-4.602

(cont. on next page)
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Table D.2 (cont.)
125973 LC50

AVGDATA paclitaxel
(Taxol)

Colon

COLO205

-4.901

125973 LC50

AVGDATA paclitaxel
(Taxol)

Colon

DLD-1

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Colon

HCC-2998

-5.165

125973 LC50

AVGDATA paclitaxel
(Taxol)

Colon

HCT-116

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Colon

HCT-15

-4.652

125973 LC50

AVGDATA paclitaxel
(Taxol)

Colon

HT29

-4.763

125973 LC50

AVGDATA paclitaxel
(Taxol)

Colon

KM12

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Colon

KM20L2

-5.704

125973 LC50

AVGDATA paclitaxel
(Taxol)

Colon

SW-620

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

CNS

SF-268

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

CNS

SF-295

-4.633

125973 LC50

AVGDATA paclitaxel
(Taxol)

CNS

SF-539

-5.037

125973 LC50

AVGDATA paclitaxel
(Taxol)

CNS

SNB-19

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

CNS

SNB-75

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

CNS

SNB-78

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

CNS

U251

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

CNS

XF498

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Melanoma

LOXIMVI

-4.617

125973 LC50

AVGDATA paclitaxel
(Taxol)

Melanoma

MALME-3M -4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Melanoma

M14

-4.602

(cont. on next page)
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Table D.2 (cont.)
125973 LC50

AVGDATA paclitaxel
(Taxol)

Melanoma

MDA-MB435

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Melanoma

M19-MEL

-4.635

125973 LC50

AVGDATA paclitaxel
(Taxol)

Melanoma

SK-MEL-2

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Melanoma

SK-MEL-28 -4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Melanoma

SK-MEL-5

-4.606

125973 LC50

AVGDATA paclitaxel
(Taxol)

Melanoma

UACC-257

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Melanoma

UACC-62

-4.622

125973 LC50

AVGDATA paclitaxel
(Taxol)

Ovarian

IGROV1

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Ovarian

OVCAR-3

-4.842

125973 LC50

AVGDATA paclitaxel
(Taxol)

Ovarian

OVCAR-4

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Ovarian

OVCAR-5

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Ovarian

OVCAR-8

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Ovarian

NCI/ADRRES

-4.614

125973 LC50

AVGDATA paclitaxel
(Taxol)

Ovarian

SK-OV-3

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Renal

786-0

-4.609

125973 LC50

AVGDATA paclitaxel
(Taxol)

Renal

A498

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Renal

ACHN

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Renal

CAKI-1

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Renal

RXF393

-4.605

125973 LC50

AVGDATA paclitaxel
(Taxol)

Renal

RXF-631

(cont. on next page)
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Table D.2 (cont.)
125973 LC50

AVGDATA paclitaxel
(Taxol)

Renal

SN12C

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Renal

TK-10

-4.604

125973 LC50

AVGDATA paclitaxel
(Taxol)

Renal

UO-31

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Prostate

PC-3

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Prostate

DU-145

-4.767

125973 LC50

AVGDATA paclitaxel
(Taxol)

Breast

MCF 7.00

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Breast

MDA-MB231/ATCC

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Breast

HS578T

-4.749

125973 LC50

AVGDATA paclitaxel
(Taxol)

Breast

MDA-N

-5.269

125973 LC50

AVGDATA paclitaxel
(Taxol)

Breast

BT-549

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Breast

T-47D

-4.602

125973 LC50

AVGDATA paclitaxel
(Taxol)

Breast

MDA-MB468

-4.622
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Table D.3. In-vitro TGI test results for paclitaxel.
nsc

endpoint expId

descriptor for
display

cell panel

cell line

test
result

125973 TGI

AVGDATA paclitaxel
(Taxol)

Small Cell
Lung

DMS114

-7.797

125973 TGI

AVGDATA paclitaxel
(Taxol)

Small Cell
Lung

DMS273

-5.434

125973 TGI

AVGDATA paclitaxel
(Taxol)

Leukemia

CCRF-CEM -4.99

125973 TGI

AVGDATA paclitaxel
(Taxol)

Leukemia

HL-60(TB)

-7.382

125973 TGI

AVGDATA paclitaxel
(Taxol)

Leukemia

K-562

-4.846

125973 TGI

AVGDATA paclitaxel
(Taxol)

Leukemia

MOLT-4

-5.12

125973 TGI

AVGDATA paclitaxel
(Taxol)

Leukemia

RPMI-8226 -5.648

125973 TGI

AVGDATA paclitaxel
(Taxol)

Leukemia

SR

125973 TGI

AVGDATA paclitaxel
(Taxol)

NonA549/ATCC -4.602
SmallCellLung

125973 TGI

AVGDATA paclitaxel
(Taxol)

NonEKVX
SmallCellLung

-4.623

125973 TGI

AVGDATA paclitaxel
(Taxol)

NonHOP-18
SmallCellLung

-4.602

125973 TGI

AVGDATA paclitaxel
(Taxol)

NonHOP-62
SmallCellLung

-5.239

125973 TGI

AVGDATA paclitaxel
(Taxol)

NonHOP-92
SmallCellLung

-5.128

125973 TGI

AVGDATA paclitaxel
(Taxol)

NonNCI-H226
SmallCellLung

-5.026

125973 TGI

AVGDATA paclitaxel
(Taxol)

NonNCI-H23
SmallCellLung

-5.504

125973 TGI

AVGDATA paclitaxel
(Taxol)

NonNCI-H322M -5.045
SmallCellLung

125973 TGI

AVGDATA paclitaxel
(Taxol)

NonNCI-H460
SmallCellLung

-4.678

125973 TGI

AVGDATA paclitaxel
(Taxol)

NonNCI-H522
SmallCellLung

-6.613

125973 TGI

AVGDATA paclitaxel
(Taxol)

NonLXFL529
SmallCellLung

-5.374

(cont. on next page)
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Table D.3 (cont.)
125973 TGI

AVGDATA paclitaxel
(Taxol)

Colon

COLO205

-6.453

125973 TGI

AVGDATA paclitaxel
(Taxol)

Colon

DLD-1

-4.612

125973 TGI

AVGDATA paclitaxel
(Taxol)

Colon

HCC-2998

-6.888

125973 TGI

AVGDATA paclitaxel
(Taxol)

Colon

HCT-116

-4.736

125973 TGI

AVGDATA paclitaxel
(Taxol)

Colon

HCT-15

-4.77

125973 TGI

AVGDATA paclitaxel
(Taxol)

Colon

HT29

-6.598

125973 TGI

AVGDATA paclitaxel
(Taxol)

Colon

KM12

-4.776

125973 TGI

AVGDATA paclitaxel
(Taxol)

Colon

KM20L2

-7.939

125973 TGI

AVGDATA paclitaxel
(Taxol)

Colon

SW-620

-4.602

125973 TGI

AVGDATA paclitaxel
(Taxol)

CNS

SF-268

-4.615

125973 TGI

AVGDATA paclitaxel
(Taxol)

CNS

SF-295

-6.31

125973 TGI

AVGDATA paclitaxel
(Taxol)

CNS

SF-539

-7.392

125973 TGI

AVGDATA paclitaxel
(Taxol)

CNS

SNB-19

-4.651

125973 TGI

AVGDATA paclitaxel
(Taxol)

CNS

SNB-75

-6.903

125973 TGI

AVGDATA paclitaxel
(Taxol)

CNS

SNB-78

-4.611

125973 TGI

AVGDATA paclitaxel
(Taxol)

CNS

U251

-5.038

125973 TGI

AVGDATA paclitaxel
(Taxol)

CNS

XF498

-7.45

125973 TGI

AVGDATA paclitaxel
(Taxol)

Melanoma

LOXIMVI

-4.835

125973 TGI

AVGDATA paclitaxel
(Taxol)

Melanoma

MALME-3M -4.777

125973 TGI

AVGDATA paclitaxel
(Taxol)

Melanoma

M14

-5.935

(cont. on next page)
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Table D.3 (cont.)
125973 TGI

AVGDATA paclitaxel
(Taxol)

Melanoma

MDA-MB435

-8.086

125973 TGI

AVGDATA paclitaxel
(Taxol)

Melanoma

M19-MEL

-4.686

125973 TGI

AVGDATA paclitaxel
(Taxol)

Melanoma

SK-MEL-2

-5.015

125973 TGI

AVGDATA paclitaxel
(Taxol)

Melanoma

SK-MEL-28 -4.602

125973 TGI

AVGDATA paclitaxel
(Taxol)

Melanoma

SK-MEL-5

-5.005

125973 TGI

AVGDATA paclitaxel
(Taxol)

Melanoma

UACC-257

-4.643

125973 TGI

AVGDATA paclitaxel
(Taxol)

Melanoma

UACC-62

-4.966

125973 TGI

AVGDATA paclitaxel
(Taxol)

Ovarian

IGROV1

-4.766

125973 TGI

AVGDATA paclitaxel
(Taxol)

Ovarian

OVCAR-3

-7.398

125973 TGI

AVGDATA paclitaxel
(Taxol)

Ovarian

OVCAR-4

-4.715

125973 TGI

AVGDATA paclitaxel
(Taxol)

Ovarian

OVCAR-5

-5.284

125973 TGI

AVGDATA paclitaxel
(Taxol)

Ovarian

OVCAR-8

-4.661

125973 TGI

AVGDATA paclitaxel
(Taxol)

Ovarian

NCI/ADRRES

-4.795

125973 TGI

AVGDATA paclitaxel
(Taxol)

Ovarian

SK-OV-3

-4.783

125973 TGI

AVGDATA paclitaxel
(Taxol)

Renal

786-0

-4.649

125973 TGI

AVGDATA paclitaxel
(Taxol)

Renal

A498

-4.749

125973 TGI

AVGDATA paclitaxel
(Taxol)

Renal

ACHN

-4.803

125973 TGI

AVGDATA paclitaxel
(Taxol)

Renal

CAKI-1

-4.866

125973 TGI

AVGDATA paclitaxel
(Taxol)

Renal

RXF393

-6.371

125973 TGI

AVGDATA paclitaxel
(Taxol)

Renal

RXF-631

(cont. on next page)
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Table D.3 (cont.)
125973 TGI

AVGDATA paclitaxel
(Taxol)

Renal

SN12C

-4.748

125973 TGI

AVGDATA paclitaxel
(Taxol)

Renal

TK-10

-5.529

125973 TGI

AVGDATA paclitaxel
(Taxol)

Renal

UO-31

-4.708

125973 TGI

AVGDATA paclitaxel
(Taxol)

Prostate

PC-3

-4.927

125973 TGI

AVGDATA paclitaxel
(Taxol)

Prostate

DU-145

-6.534

125973 TGI

AVGDATA paclitaxel
(Taxol)

Breast

MCF 7.00

-4.82

125973 TGI

AVGDATA paclitaxel
(Taxol)

Breast

MDA-MB231/ATCC

-5.173

125973 TGI

AVGDATA paclitaxel
(Taxol)

Breast

HS578T

-7.078

125973 TGI

AVGDATA paclitaxel
(Taxol)

Breast

MDA-N

-7.245

125973 TGI

AVGDATA paclitaxel
(Taxol)

Breast

BT-549

-5.924

125973 TGI

AVGDATA paclitaxel
(Taxol)

Breast

T-47D

-4.602

125973 TGI

AVGDATA paclitaxel
(Taxol)

Breast

MDA-MB468

-5.854
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APPENDIX E ⏤ Vaporization

Table E.1.

Composition of formulations containing paclitaxel.

Composition Ratio
Control: Paclitaxel only

Total Quantities Added

30 mg Paclitaxel
15 mL EtOH
1:1 CuCl2/Paclitaxel
30 mg Paclitaxel
5.99 mg CuCl2
15 mL EtOH
5:1 CuCl2/Paclitaxel
30 mg Paclitaxel
29.9 mg CuCl2
15 mL EtOH
1:1 FeCl3/Paclitaxel
30 mg Paclitaxel
9.5 mg FeCl3
15 mL EtOH
5:1 FeCl3/Paclitaxel
30 mg Paclitaxel
47 mg FeCl3
15 mL EtOH
5:5:1 CuCl2/FeCl3/Paclitaxel 30 mg Paclitaxel
29.9 mg CuCl2
47 mg FeCl3
15 mL EtOH

Figure E.1.

Total Quantity per mL
of Solution
2 mg Paclitaxel
2 mg Paclitaxel
0.399 mg CuCl2
2 mg Paclitaxel
1.99 mg CuCl2
2 mg Paclitaxel
0.63 mg FeCl3
2 mg Paclitaxel
3.13 mg FeCl3
2 mg Paclitaxel
1.99 mg CuCl2
3.13 mg FeCl3

LC-MS results following vaporization of Cu-PAC in ethanol in a 3:1 mixture of
PG/VG using the KangerTech Vapor Pen.
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Figure E.2.

LC-MS results following vaporization of Cu5-PAC in ethanol in a 3:1 mixture of
PG/VG using the KangerTech Vapor Pen.

Figure E.3.

LC-MS results following vaporization of Fe-PAC in ethanol in a 3:1 mixture of
PG/VG using the KangerTech Vapor Pen.
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Figure E.4.

LC-MS results following vaporization of Fe5-PAC in ethanol in a 3:1 mixture of
PG/VG using the KangerTech Vapor Pen.

Table E.2.

Comparison of flask weights after each pulse of a 3:1 ratio of PG/VG with EtOHPAC across various temperatures.
Green numbers indicate the change in weight from the starting weight of the flask.
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Table E.3.

Comparison of flask weights after each pulse of a 1:3 ratio of PG/VG with EtOHPAC across various temperatures.
Green numbers indicate the change in weight from the starting weight of the flask.

Table E.4.

Comparison of flask weights after each pulse of a 1:1 ratio of PG/VG with EtOHPAC across various temperatures.
Green numbers indicate the change in weight from the starting weight of the flask.

120
Table E.5.

Comparison of flask weights after each pulse from the highest yielding samples of
3:1 PG/VG, 1:3 PG/VG, and 1:1 PG/VG with EtOH-PAC.
Green numbers indicate the change in weight from the starting weight of the flask.

